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Abstract: Receptor tyrosine kinases (RTKs) are membrane-based sensors that enable rapid
communication between cells and their environment. Evidence is now emerging that interdependent
regulatory mechanisms, such as membrane trafficking, ubiquitination, proteolysis and gene
expression, have substantial effects on RTK signal transduction and cellular responses. Different RTKs
exhibit both basal and ligand-stimulated ubiquitination, linked to trafficking through different
intracellular compartments including the secretory pathway, plasma membrane, endosomes and
lysosomes. The ubiquitin ligase superfamily comprising the E1, E2 and E3 enzymes are increasingly
implicated in this post-translational modification by adding mono- and polyubiquitin tags to RTKs.
Conversely, removal of these ubiquitin tags by proteases called de-ubiquitinases (DUBs) enables RTK
recycling for another round of ligand sensing and signal transduction. The endocytosis of basal and
activated RTKs from the plasma membrane is closely linked to controlled proteolysis after trafficking
and delivery to late endosomes and lysosomes. Proteolytic RTK fragments can also have the capacity
to move to compartments such as the nucleus and regulate gene expression. Such mechanistic
diversity now provides new opportunities for modulating RTK-regulated cellular responses in health
and disease states.
Keywords: receptor tyrosine kinases; ubiquitin; ubiquitin ligases; de-ubiquitinases; signal transduction;
trafficking; proteolysis
1. Introduction
Receptor tyrosine kinases (RTKs) represent a family of integral membrane proteins exemplified
in humans by 58 proteins divided into 20 subfamilies. These include the epidermal growth factor
receptor (ErbB), vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor
receptor (PDGFR) and insulin-like receptor (IR) families [1–3] (Figure 1). All RTKs exhibit similar
domain organisation with an extracellular ligand-binding domain, a single transmembrane region
with α-helical propensity followed by a cytoplasmic domain with tyrosine kinase activity. The unique
ligand-binding properties of different RTKs are determined by features in the extracellular domain
such as fibronectin III-like repeats [4,5], cysteine-rich motifs [6,7], immunoglobulin-like domains [8],
leucine-rich and glycine-rich repeats/motifs [9,10] (Figure 1). Interestingly, two branches of the RTK
superfamily contain long ~60–100 residue inserts within the TK domain, with potentially significant
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regulatory roles. Deletion of the kinase insert from VEGFR2 increases tyrosine kinase activity in the
activation loop, but also induces a loss of Y1175 phosphorylation and diminished signaling through
phospholipase Cγ1 (PLCγ1) [11].
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Figure 1. Overview of the domain architecture of the 20 human RTK families. Each RTK contains five 
fundamental structures: an extracellular ligand-binding domain, a short helical transmembrane 
region, a juxtamembrane region, cytoplasmic domain with tyrosine kinase activity and a flexible C-
terminal tail region. The extracellular ligand-binding domain displays significant variability between 
families, with notable additions of motifs rich in glycine, cysteine or leucine and immunoglobulin-
like domains amongst others. The insulin receptor family differs from the rest due to its pre-
assembled multimeric complex. 
Ligand engagement with the RTK extracellular domain induces conformational changes 
resulting in RTK activation and downstream signal transduction. For RTKs such as the ErbB, VEGFR 
or PDGFR families, RTK binding to ligand promotes homo- or heterodimer formation (within each 
family). In other cases, such as IR, a pre-assembled complex is activated by ligand binding (Figure 1). 
Interestingly, substantial variability can be observed in the extent of monomeric and pre-formed 
dimeric RTKs within the same RTK family [12]. One consistent aspect of ligand binding to RTK is 
transmission of conformational changes through each RTK, resulting in conformational changes in 
the TK domain [12]. Such changes in TK disposition invariably lead to phosphorylation of 
neighbouring proteins including other RTKs, signaling adaptors, enzymes and kinases [13]. 
Activation of the TK domain causes hydrolysis of bound ATP, resulting in the transfer of the γ 
phosphate group onto the hydroxyl group of a nearby tyrosine side chain. Tyrosine 
autophosphorylation of the RTK is an early and rate-determining step in controlling the flow of 
information into different signaling circuits, which in turn modulate cellular responses. Importantly, 
such modifications are also reversible via the action of protein tyrosine phosphatases (PTPs), which 
enhances flexibility in controlling signaling output and cell function. 
2. Signal Transduction 
The details of RTK-mediated signal transduction are covered only briefly here, to set the 
subsequent discussion in context. In-depth analysis of the mechanisms of RTK-mediated signal 
transduction is featured in this thematic issue, and reviews elsewhere [3,14–16]. Briefly, RTKs can 
undergo activation by both membrane-bound and soluble ligands. RTK activation by ligand induces 
Figure 1. Overview of the domain architecture of the 20 human RTK families. Each RTK contains
five fundamental structures: an extracellular ligand-binding domain, a short helical transmembrane
region, a juxtamembrane region, cytoplasmic domain with tyrosine kinase activity and a flexible
C-terminal tail region. The extracellular ligand-binding domain displays significant variability between
families, with notable additions of motifs rich in glycine, cysteine or leucine and immunoglobulin-like
domains amongst others. The insulin receptor family differs from the rest due to its pre-assembled
multimeric complex.
Ligand engagement with the RTK extracellular domain induces conformational changes resulting
in RTK activation and downstream signal transduction. For RTKs such as the ErbB, VEGFR or
PDGFR families, RTK binding to ligand promotes homo- or heterodimer formation (within each
family). In other cases, such as IR, a pre-assem led complex is activated by ligand bi ing (Figure 1).
Interestingly, substantial variability c n be observed in the extent of monomeric and pre-formed
dimeric RTKs withi the same RTK family [12]. One consist nt aspect of ligand bi ding to RTK is
transmission of conformational s through each RTK, result ng in conformati nal changes in the
TK domain [12]. Such changes in TK disposition invariably lead to phosphorylation of neighbouring
proteins including other RTKs, signaling adaptors, enzymes and kinases [13]. Activation of the TK
domain causes hydrolysis of bound ATP, resulting in the transfer of the γ phosphate group onto
the hydroxyl group of a nearby tyrosine side chain. Tyrosine autophosphorylation of the RTK is an
early and rate-determining step in controlling the flow of information into different signaling circuits,
which in turn modulate cellular responses. Importantly, such modifications are also reversible via
the action of protein tyrosine phosphatases (PTPs), which enhances flexibility in controlling signaling
output and cell function.
2. Signal Transduction
The details of RTK-mediated signal transduction are covered only briefly here, to set the subsequent
discussion in context. In-depth analysis of the mechanisms of RTK-mediated signal transduction is
featured in this thematic issue, and reviews elsewhere [3,14–16]. Briefly, RTKs can undergo activation by
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both membrane-bound and soluble ligands. RTK activation by ligand induces tyrosine phosphorylation
at multiple sites within the cytoplasmic domain, which triggers recruitment of specific adaptors and
enzymes to the cytosolic face of the plasma membrane. In the case of EGFR, activation results in the
recruitment of Grb2 adaptor which binds to specific phosphotyrosine epitopes, further resulting in binding
to the son-of-sevenless (Sos) guanine exchange factor (Figure 2) [17]. Recruitment of Sos to this locality,
enables interaction with plasma membrane-localized Ras, a proto-oncoprotein and GTP-hydrolyzing
enzyme (GTPase). Sos stimulates Ras-GDP to exchange the bound nucleotide and move into the Ras-GTP
state, thus triggering a set of subsequent downstream reactions which is the canonical mitogen-activated
protein kinase (MAPK) pathway (Figure 2). Other downstream targets of activated EGFR include PLCγ1,
which is again recruited by binding to specific phosphotyrosine epitopes, followed by hydrolysis of
plasma membrane-localized phospholipid, phosphatidylinositol-4,5-bisphosphate (PIP2). This hydrolysis
generates membrane-bound diacylglycerol and soluble inositol-1,4,5-trisphosphate (IP3), rapidly diffusible
second messengers with potent effects on cell function (Figure 2). Similar pathways can be activated by the
different members of the RTK superfamily; however, the location, intensity and duration of such signaling
events exhibit unique patterns depending on ligand, RTK and cell-type. In this manner, the complexity of
signaling mechanisms has evolved to exquisitely control cell, tissue and animal function.
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3. Plasma Membrane Endocytosis 
An increasingly important concept in RTK functionality is membrane trafficking. The amount of 
plasma membrane RTK (and thus free RTK available for exogenous ligand sensing) is substantially 
influenced by the rate of newly synthesized RTK arriving from the secretory pathway, balanced by 
the rate of internalization (endocytosis) at the plasma membrane. Typically, a newly synthesized RTK 
polypeptide is made as a Type I integral membrane protein which undergoes translocation into the 
endoplasmic reticulum (ER), signal peptide cleavage, usually followed by initial stages of N- and O-
linked glycosylation [18]. Interestingly, a recent study suggests that activation of EGFR causes 
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Figure 2. SignalingEpithelial growth factor receptor signal transduction. Stimulation of EGFR
with the EGF ligand initiates a series of signaling cascades that significantly alter cellular
function. EGFR activation triggers the recruitment of Grb2 and son-of-sevenless to the plasma
membrane, promoting Ras-GDP to Ras-GTP transition and activation of the MAPK pathway.
Separately, EGFR activation stimulates PLCγ1 activity and PIP2 hydrolysis to release diacylglycerol
and IP3. EGF also mediates downstream signaling through the PI3K/Akt and JAK/STAT pathways to
induce cellular changes.
3. Plasma Membrane Endocytosis
An increasingly important concept in RTK functionality is membrane trafficking. The amount of
plasma membrane RTK (and thus free RTK available for exogenous ligand sensing) is substantially
influenced by the rate of newly synthesized RTK arriving from the secretory pathway, balanced by
the rate of internalization (endocytosis) at the plasma membrane. Typically, a newly synthesized
RTK polypeptide is made as a Type I integral membrane protein which undergoes translocation
into the endoplasmic ret culum (ER), signal peptide cleavage, usually followed by ini ial stages
of N- and O-linked glycosylation [18]. Interestingly, a recent study suggests that activation of
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EGFR causes increased gene expression of components of the COPII machinery that mediates
ER-to-Golgi trafficking [19], suggesting that modulating RTK secretion could have major impacts on
animal physiology.
Subsequent exit from the ER and delivery to the Golgi complex is marked by extensive
glycosylation within the different Golgi subcompartments (cis, medial, trans). Exit from the most distal
Golgi subcompartment trans-Golgi network (TGN) via the constitutive secretory pathway results in
delivery to the plasma membrane. Notably, some RTKs display steady-state or distinct patterns of Golgi
localization, but the mechanisms underlying such distribution are unclear. For example, c-Met and
EGFR are both routed through the Golgi complex to the basolateral plasma membrane in polarized
epithelial cells [20,21]. VEGFR1 is reported to be largely present within a Golgi-like subcompartment
in endothelial cells but translocates to the cell surface via a cytosolic calcium ion-dependent membrane
trafficking route [22]. VEGFR2 shows significant steady-state Golgi localization in a SNARE- and
microtubule-dependent manner with functional consequences for signal transduction and new blood
vessel sprouting i.e., angiogenesis [23–25]. Both tropomysin receptor kinase A (TrkA) and EGFR
trafficking through the Golgi complex is SNARE-dependent with functional consequences for signal
transduction and functionality [26,27]. Interestingly, one study reports that diffusible reactive oxygen
species (ROS) can promote ligand-independent phosphorylation of VEGFR2 within the Golgi complex,
resulting in proteolysis and loss of transport to the cell surface [28]. A recent study also suggests that
ubiquitination programs the marked loss of maturation of newly synthesized VEGFR2, associated
with a reduction in cell surface expression, loss of signaling and diminished levels of angiogenesis [29].
Complex mechanisms exist to direct both basal (non-activated, resting, steady-state) and activated
RTK into transport pathways that deliver these membrane-bound enzymes to the endosome-lysosome
network. Endocytosis of RTKs is well-documented, with clathrin-dependent endocytosis (CDE)
of both basal and activated RTKs (Figure 3). STAT3 signaling downstream of PDGFRβ is reliant
upon its internalization, which can be mediated by CDE [30]. Regulation of EGFR [31–33] and
VEGFR2 [34–37] internalization by CDE impacts on the intensity and duration of downstream
signaling. Furthermore, EGF stimulation of EGFR induces PLCγ1 and calcium-dependent signaling
responsible for the selective internalization of the receptor by CDE [38]. The vascular regulator
Tie2 is linked to internalization via CDE on endothelial cells [39]. There is also evidence that
EGFR activation leads to phosphorylation of components of the CDE machinery, thus modulating
the rate of internalization [40,41]. Signaling adaptors such as Grb2, which are recruited to EGFR,
further modulate CDE [42]. Recent evidence suggests that the adaptor intersectin-s is an important
factor in CDE-dependent internalization of EGFR and downstream signaling, and represents a key
regulator of recycling [43]. Plasma membrane microdomains containing either lipid rafts or CDE
machinery can specifically recruit EGFR [44,45]. It has also been postulated that EGFR undergoes
differential post-translational modifications and proteolytic fates depending on its association with
CDE or lipid rafts [46]. One likelihood is that CDE modulates RTK-linked early trafficking events and
signal transduction but does not regulate proteolysis in later compartments such as late endosomes and
lysosomes [32].
However, clathrin-independent endocytosis (CIE) has also been documented for RTKs such as
EGFR, PDGFRβ and VEGFR2, with roles for lipid rafts, caveolae and macropinocytosis postulated
to direct the internalization and delivery to endosomes [30,47,48]. EGFR association with caveolae
and lipid rafts is dependent on a cysteine-rich region of the extracellular domain close to the
transmembrane region [49], suggesting involvement of accessory membrane proteins or co-receptors.
VEGFR2 association with CIE-dependent pathways such as lipid rafts and caveolae [50] is balanced by
internalization via CDE [22,34]. Another RTK called ROR is implicated in functioning as a scaffold to
bind cavin-1 and caveolin-1, structural components of caveolae [51]. RTK ligands, such as insulin, EGF,
and VEGF-A, stimulate c-Src recruitment, activation and tyrosine phosphorylation of caveolin-1 [52–54].
An emerging theme from multiple studies is that RTK recruitment to different microdomains is dynamic,
and potentially activation-dependent. RTK association with either CDE or CIE leads to modulation
Cells 2018, 7, 22 5 of 24
of internalization, trafficking and proteolysis, which has major consequences for downstream signal
transduction events. It is likely that RTK activation could promote recruitment of downstream effectors
(e.g., c-Src) or directly stimulate phosphorylation of structural components of CDE and/or CIE pathways
that promote or inhibit inclusion into microdomains. Such microdomain clusters could mediate stable
plasma membrane association or specify internalization and delivery to endosomes.
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An important aspect of biochemical regulation of eukaryote function is the use of small, 
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Figure 3. Ubiquitin-mediated internalization of the RTK. RTKs are internalized via both
clathrin-dependent (CDE) and clathrin-independent (CIE) pathways following ubiquitination.
Essential endocytic components including epsin and eps15 are recruited to the ubiquitinated RTK.
Epsin contains two ubiquitin-binding motifs allowing its recognition of the internalization signal,
enabling uptake via both CDE and CIE. Both pathways converge in endosomes following the shedding
of clathrin (orange circles) from the vesicular surface. Once within the endocytic vesicle, the RTK is
delivered by fusion with the Rab5a-expressing early endosome. At this point, RTK fate is decided
by either direction to Rab4a-expressing endosomes for recycling or to multivesicular bodies for
lysosomal degradation.
Increasingly, it has been postulated that many activated RTKs including EGFR and VEGFR2
trigger important signaling events in endosomes, including the canonical mitogen activated protein
kinase (MAPK) and phosphoinositide 3-kinase (PI3K) signaling pathways [31,55,56]. Enhanced EGFR
signaling is observed when trafficking from early to late endosomes is slowed, indicating the importance
of the endosomal compartment as a signaling station [57]. Another RTK, c-Met, upon activation,
requires endocytosis and deliver to ndosomes to signal through the STAT3 pathway [58].
The capacity of an activated RTK to signal from a variety of endosomal compar ments appears likely.
Indeed, c-Met al.so displays differe tial signaling p tterns depending upon its l alization within
peripheral r perinuclear endosomes [59]. Act vated PDGFR ca signal to the PI3K and PLCγ1 pathways
from endosomes, lea ing to ph siological responses [60]. Notably, blocking VEGFR2 endocytosi at the
cell surface diminishes signal transduction due to reduced endosome occupancy [35]. The extended
residency of VEGFR2 within sorting endosomes is associated with a loss of signaling, demonstrating the
complexity in endosomal regulation of signal transduction downstream of the RTK [61]. Further RTK
trafficking to multivescular bodies and lysosomes is dependent on ubiquitin chain recognition closely
linked to proteolysis and signal cessation.
4. U iquitin Modificatio and Ubiquitin Ligases
An important aspect of biochemical regulation of eukaryote function is the use of small,
ubiquitin-related protein tags to target proteins for destruction to enable down-regulation and recycling
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of protein-based components. We now know that such ubiquitin-like tags can cause three different
outcomes: target proteins for proteolysis, target proteins to specific locations within a cell and/or
modulate biochemical or enzymatic activity. In the case of RTKs, there are increasing examples of
RTK modification by the attachment of monomer or polymeric forms of ubiquitin to lysine residues
at one or more sites within their cytoplasmic domains [62–64]. Recently, it has been noted that basal
(non-activated) VEGFR2 undergoes ubiquitination, which consequently has substantial effects of
ligand-stimulated signal transduction and cellular responses [65]. The attachment of ubiquitin to
RTKs such as the ErbB and VEGFRs [65–67] appears to mediate inclusion into CDE and efficient
delivery through the endosome-lysosome system for proteolysis. In this way, RTK degradation enables
cessation of signal transduction.
Ubiquitin is a highly conserved 76 amino acid polypeptide encoded by 4 human genes, i.e., UBB,
UBC, UBA52 and RPS27A [68,69]. UBB and UBC represent polymeric concatemers with three and nine
consecutive repeats respectively. UBA52 and RPS27A encode for monoubiquitin fused to the ribosomal
proteins L40 and S27A. Both ubiquitin forms are processed to release free ubiquitin monomers to maintain
an intracellular ‘free’ ubiquitin pool. This steady-state ubiquitin pool is utilized by 3 enzyme families,
termed E1, E2 and E3 ubiquitin ligases. The E1 (ubiquitin activating enzymes), E2 (ubiquitin conjugating
enzymes) and E3 (ubiquitin ligases), work in concert to orchestrate addition of ubiquitin to the ε-amino
side chain on specific lysine residues within a protein substrate or target. The E1 family has 10 members,
with only 2 that are specific to ubiquitin chain addition. These 2 enzymes, UBA1 [70] and UBA6 [71],
are structurally similar and are able to initiate the first step of the ubiquitination cascade (Figure 4).
The remaining 8 E1 family members are UBA2 [72], UBA3 [73], UBA4/MOCS3 [74], UBA5 [75], UBA7 [76],
NAE1 [77], SAE1 [72] and ATG7 [78], which are responsible for activation of ubiquitin-like tags for
addition to target substrates. These protein tags include small ubiquitin-related modifier (SUMO),
neural precursor cell expressed, developmentally downregulated 8 (NEDD8), and ubiquitin-fold modifier
(Ufm). Although sumoylation, neddylation and ufmylation use different biochemical pathways from
ubiquitination, the essential features of the cellular machinery involved is mechanistically similar, and thus
require interactions with downstream E2 and E3 enzymes.
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Figure 4. Ubiquitin activation and conjugati 2 enzymes. The E1 enzyme binds to either
ubiquitin or ubiquitin-like modifier and Mg-ATP, resulting in ATP hydrolysis. This allows the adenylation
of the ubiquitin/ubiquitin-like modifier and release of pyrophosphate. This is followed by the formation
of a thioester bond between a cysteine residue within the E1 and the C-terminal glycine of the ubiquitin
molecule accompanied by release of AMP. The E1 subsequently undergoes a second round of ubiquitin
loading at the adenylation site prior to interaction with the E2. The transfer of the ubiquitin from E1 to a
cysteine residue on the E2 occurs via transthioesterification, allowing the release of the E1.
E1s bind their cognate ubiquitin or ubiquitin-like modifier and Mg-ATP linked to subsequent
ATP hydrolysis to AMP and pyrophosphate, enabling thioester bond formation between a critical
cysteine side chain and the carboxyl-terminal glycine in ubiquitin (Figure 4). This E1-Ub subsequently
undergoes a second round of ubiquitin linkage and the dual-loaded E1-Ub species is now competent
for interaction with E2 enzymes (Figure 4). Recent evidence demonstrates that UBA5 differs from
the other E1 enzymes in its requirement for trans-binding of the UFM1 to the UBA5 homodimer [79].
UFM1 binding stabilises the UBA5 homodimer, enhancing ATP binding [80]. Recruitment of an
appropriate E2 to E1-Ub is a critical event in the progression of the ubiquitination cycle, and handover
of these ‘charged’ ubiquitin substrate onto E2 enzymes (Figure 4).
This E2 ubiquitin ligase family encoded by ~45 genes is defined by a conserved ~150 residue
ubiquitin-conjugating (UBC) domain, exemplified by a cysteine residue needed for the transfer of
the charged ubiquitin (from E1) via a thioester bond with E2, and a histidine-proline-asparagine
(HPN) triad that regulates E2 activity. The histidine residue represents a critical structural element,
providing functional stability within the E2 enzyme [81]. The asparagine residue within the HPN
triad catalyses the formation of an isopeptide bond between the ‘charged’ ubiquitin and the target
substrate. This occurs by stabilization of the oxyanion intermediate which regulates interaction of the
E2-ubiquitin thioester with target lysine side chain on the target substrate [81,82]. However, this step
also requires E2 interaction with a corresponding or specific E3 ubiquitin ligase. The E3 protein can
function as an adaptor but can also possess catalytic properties. Such features enable the target
substrate to achieve close molecular proximity to the charged E2-Ub species. Although the E2 family
already provides diversity, the E3 family is even more diverse with >700 E3s encoded within the
human genome; the exact number of E3 family members uncertain at present. Substrate specificity is
dependent on the E2:E3 complex, with a single E2 able to interact with multiple E3s.
E3 family members can be subdivided into three groups, including the homologous to the
E6AP carboxyl terminus (HECT), really interesting new gene (RING) and RING between RING
(RBR) groups [83] (Figure 5A). The HECT group, which was the first E3 class to be described,
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has 28 members [84,85]. The HECTs include a C-terminal domain containing a catalytic cysteine
residue and an N-terminal domain with an E2 binding motif [86] (Figure 5A). RING E3s comprise
the largest group, with at least 600 members, including the structurally similar U-box proteins [87],
and contain conserved cysteine and histidine residues in the core that bind zinc ions. The RBR group
members have two RING domains separated by an in-between RING domain [83].
Mechanistically, HECT enzymes form an intermediate thioester bond with the carboxyl-terminus
glycine residue of the charged ubiquitin (attached to E2) prior to transfer to the target substrate [88]
(Figure 5B). In contrast, RING members appear to facilitate direct transfer of the charged ubiquitin from
E2 to the lysine side chain on the target substrate [89]. The formation of the E2-Ub:E3 RING complex
could facilitate a change in the ‘closed’ conformation in the E2-Ub intermediate, thereby priming the
thioester linkage for nucleophilic attack on the closely aligned lysine(s) within the target substrate [90]
(Figure 5B). RBRs display hybrid features of both RING and HECT groups. Typically, an RBR has E2
binding capacity through the N-terminal RING1 domain and a catalytic cysteine residue within the
C-terminal RING2 domain allows transfer of charged ubiquitin from the E2 intermediate to the RBR,
before being conjugated to a specific lysine side chain on the target substrate (Figure 5B).
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Figure 5. HECT, RING and RING between RING E3 families differ in their mechanism of ubiquitin
transfer to substrates. (A) The major E3 families HECT, RING and RING between RING display distinct
structures that determine their mode of ubiquitin transfer. HECT E3s have a hinge loop connecting their
N-lobe, which contains the E2 binding site, with their C-lobe containing the cysteine residue critical
for ubiquitin linkage. RING E3s typically display conserved cysteine and histidine residues within
their core structure that stabilise the presence of central zinc ions. The loop structures surrounding the
zinc ions represent the conserved E2 binding site. RING between RING E3s are complex multidomain
proteins containing two RING domains separated by an ‘in-between RING’ domain. The N-terminal
RING contains the E2 binding site and the C-terminal RING contains the catalytic cysteine residue.
(B) The mechanism of ubiquitin transfer differs between the E3 families. HECT E3s bind to the substrate
and ubiquitin-charged E2, which induces a change in the orientation of the hinge loop to move the
C-lobe and catalytic cysteine into closer proximity to the ubiquitin. Ubiquitin is then transferred from
the E2 to the C-lobe cysteine, enabling a return to the original lobe orientation and transfer of the
ubiquitin from the HECT E3 to a lysine residue on the substrate. RING E3s differ significantly from
this as their role is more of a scaffold or adaptor that binds both E2 and substrate. This brings both
ubiquitin and substrat into close proximity and enables the direct tr sfer of ubiquitin from the E2 to
a lysin residue on the substrate. Mechanistic lly, the RBR E3 acts in a more similar mann to their
HECT cou terparts. The RBR binds the E2-ubiquitin to its N-terminal RING and binds the substrate
with its C-terminal RING. An intermedi te thioester bond s form d b tween the ubiquitin and the
C-terminal RING. The ubiquitin molecule is subseq ently transfer ed to a lysine residue on the target
substrate that is bound by the C-terminal E3 RING.
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Multiple types of ubiquitination chains attached to target substrates are dependent on the 7 lysine
residues (K6, K11, K27, K29, K33, K48, K63) and free primary amino terminus in the N-terminal
methionine (M1) within the ubiquitin polypeptide [91]. The nature of polyubiquitin chains is highly
variable, with the potential for several branches of ubiquitin chains to form at different lysine
residues on the same substrate-bound ubiquitin, and the possibility of mixed-chain species with
other ubiquitin-like proteins also being found within the same chain alongside ubiquitin [92].
This corresponds to a significant number of potential effects on cellular function, although limited data
is available for atypical chain linkages. One such function of ubiquitination that has been explored in
some depth is in the DNA damage response pathway [93–98]. K6 and K33 polyubiquitin chains in
particular have been linked with the DNA damage response [99], alongside K27 chain modification
of chromatin [100], although further research is necessary to confirm these roles. Branched K11
polyubiquitin chains demonstrate more efficient trafficking of the tagged substrate to the proteasome
than other types of ubiquitin linkage, suggesting a major role in protein degradation [101]. K29 chains
may play an inhibitory role in signaling through the Wnt/β-catenin pathway [102]. K48 chains are
the most commonly observed linkage type and provide a strong signal for protein degradation [103].
K63 chains are also associated with protein degradation [104], as well as cell signaling pathways [105].
Mixed K48-K63 branched species may also play a major role in NF-κB signaling [106], but also direct
tagged proteins for degradation [107]. M1 linear ubiquitin chains are strongly associated with innate
immune signaling [108] and have a well-documented role in TNF receptor function [109].
5. Plasma Membrane RTK Ubiquitination and Sorting
Integral membrane proteins such as RTKs appear to undergo both monoubiquitination,
multi-monoubiquitination and polyubiquitination (also at single and multiple sites) on the protein
backbone via attachment to lysine side chains. The overall effects on the RTK may differ substantially
depending upon the exact location of the sites of attachment, number of ubiquitin linkages, and exact
nature of ubiquitin chains. Ubiquitination of cell surface receptors is generally thought to target these
proteins for destruction in the late endosome and lysosome; however, the exact mechanism(s) remain
elusive. Currently, the view is ubiquitinated RTKs exhibit increased proteolysis, resulting in cessation
of signaling compared to non-ubiquitinated RTKs [110]. RTK ubiquitination is thought to promote
endocytosis via CDE and/or CIE [111,112]. Modifying RTK by attachment of different ubiquitin tags
is a complex strategy to control receptor availability at the plasma membrane and dictate trafficking
before recycling or proteolysis. It is well-established that for RTKs such as EGFR, ErbB2, MuSK [113],
TrkA [114] and VEGFR2 [6,34], ligand activation precedes ubiquitination and is linked to increased
degradation in the endosome-lysosome network. Activation of TrkA by nerve growth factor occurs
in response to ligand stimulation and can be mediated by both multimonoubiquitination [114] and
polyubiquitination [115,116]. VEGFR2 ubiquitination is associated with downregulated cell surface
expression and blockade of receptor ubiquitination significantly impairs endocytosis resulting in
increased cell surface levels [29]. Similarly, monoubiquitination of activated PDGFR or EGFR is
sufficient to stimulate endocytosis, reduce cell surface levels and availability for exogenous ligand
binding [117]. Activated EGFR displaying K63-linked polyubiquitin chains are subjected to increased
proteolysis [118]. Many studies suggest that RTK ubiquitination can be a signal to promote endocytosis
resulting in down-regulation of cell surface levels, and this is irrespective of the type of ubiquitin
chain attachment.
Transport from the cell surface necessitates the involvement of a group of proteins known as
the endosomal sorting complexes required for transport (ESCRT). ESCRT recognition of the type of
ubiquitin attachment conjugated to RTKs is dependent on endocytic machinery such as the proteins
epsin and Eps15, both of which contain ubiquitin-interacting motifs (UIMs) [119–121]. ESCRTs play
key roles in the recognition and trafficking of ubiquitinated EGFR. However, ESCRT-0 and ESCRT-II
complexes are dispensable for EGFR recycling back to the plasma membrane from endosomes [122].
The Gαs protein has recently been demonstrated to bind to the ubiquitinated Hrs component of
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ESCRT-0, and depletion of Gαs delays EGFR degradation by impeding trafficking into lysosomes [123].
ESCRT-III proteins also have a demonstrable role in regulating EGFR trafficking, as evidenced in
recent studies with depletion of ESCRT-III regulatory proteins CC2D1A/CC2D1B, which curtailed
EGFR signaling and accelerated EGFR degradation [124]. Studies assessing the internalisation of c-Met
and EGFR have both demonstrated requirement for a complex comprising the proto-oncoprotein and
E3 ligase (Cbl), CIN85 and endophilin [125,126]. This early endocytosis-associated complex acts to
encapsulate the receptor into early invaginations at the plasma membrane and promote inclusion into
endocytic vesicles. Such vesicles then fuse with early endosomes, a key compartment for RTK signal
transduction and sorting. Inhibition of Cbl association with CIN85 by the GTP-binding protein SEPT9
impairs EGFR ubiquitination and degradation [127].
6. RTK Ubiquitination, Recycling and Proteolysis
Plasma membrane RTK down-regulation as a consequence of ubiquitination was conventionally
viewed to program cessation of signal transduction after reaching multivescular bodies (MVBs) or
late endosomes, followed by degradation in lysosomes. This would provide a means for RTK signal
attenuation or cessation. Whilst sorting of EGFR into MVBs before proceeding to lysosomes for
proteolysis is well-established [128,129], other studies also suggest that EGFR, TrkA and VEGFR2
undergo proteolysis by a proteasome-regulated pathway [9,116,130].
RTKs can be recycled from endosome-to-plasma membrane to maintain sensitivity to exogenous
ligand, although it is unclear whether signaling continues during recycling [131–137]. Mutation of
specific lysines within the FGFR1 cytoplasmic domain suggest that the efficiency of recycling is
increased and targeting for degradation is diminished, facilitating increased signal transduction [138].
The EGFR model continues to provide new insights and its ability to bind different ligands
such as EGF and transforming growth factor-α indicate programming for different signaling
and proteolysis outcomes. EGFR:EGF activation stimulates degradation whereas EGFR:TGF-α
stimulates recycling to the cell surface [139]. One possibility is that within the lower pH in
endosomes, EGF-EGFR remains stably bound but TGF-α rapidly dissociates, allowing efficient EGFR
recycling from endosome-to-plasma membrane. Other EGFR ligands suggest the capacity to program
differential post-translational modifications which affect EGFR fate through trafficking, recycling or
proteolysis [140–142]. The family of E1, E2 and E3 ubiquitin ligases is thus critical in determining how
RTK fate and signal transduction properties are regulated in this context.
Although RTK ubiquitination is an increasingly important aspect of cellular regulation, there is
a dearth of information on E1, E2 and E3 enzymes in this process. Of note, a recent study identified
the E1 family member, UBA1, in regulating the ubiquitination of basal (non-activated) VEGFR2
but surprisingly, not for ligand-activated VEGFR2 [65]. This study puts forward the idea that at
least 2 different mechanisms of ubiquitination exist, one to modify basal RTKs, and another pathway
which targets activated RTKs [65]. It is likely that other RTKs may also exhibit such regulation.
The roles for the other 9 E1 family members in RTK regulation remain to be described. There is
also increasing evidence for SUMOylation of RTKs, linked to nuclear translocation of proteolytic
fragment(s) of the processed RTK e.g., insulin-like growth factor 1 receptor (IGF-1R) [143] and
ErbB4 [144], suggesting roles for E1 members which regulate SUMOylation. The identification and
mechanistic role of E2 ubiquitin ligases in RTK modification remain to be elucidated. Studies on
IGF-1R SUMOylation and nuclear translocation found that such effects were regulated by the E2 family
member and SUMO-conjugating enzyme UBE2I [145].
7. RTK Targeting by E3 Ubiquitin Ligases
The best-studied aspect of RTK ubiquitination is interaction with E3 ubiquitin ligases that affect
signal transduction, trafficking and proteolysis. Many RTKs, including EGFR, PDGFRs, TrkA, Ret,
EphRs, FGFRs and VEGFRs, are targeted for ubiquitination by the E3 enzyme Cbl, a proto-oncoprotein
that modulates signal transduction, membrane trafficking and proteolysis [146–158]. Cbl also
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regulates movement of EGFR out of the early endosomes and facilitates ubiquitination, leading to its
proteolysis [147]. Cbl deficiency or disruption of its ability to bind target substrates causes increased
PDGFRα and FGFR2 cell surface levels concomitant with reduced ubiquitination [149]. Both c-Cbl
and related Cbl-b can also modulate PDGFRβ status with subsequent effects on endocytosis and
signal transduction [150]. Other E3 enzymes have been implicated in EGFR modification, including
UBE4B [159] and Cullin-3/speckle-type POZ protein-like, SPOPL [160]. Whereas UBE4B is recruited
to endosomes and may directly regulate EGFR ubiquitination, Cullin-3/SPOPL targets Eps substrate
15 (Eps15) on endosomes [160], which regulates EGFR recycling [131]. MuSK ubiquitination has been
reported to be effected by the E3 ligase PDZ domain-containing ring finger 3, although its role in the
endocytosis of other RTKs has not been established [113]. Intriguingly, a recent report suggests that
the E3 family member, RNF121, binds to newly synthesized VEGFR2 and impairs its maturation and
transport to the plasma membrane [29].
Insulin receptor (IR) cell surface expression is regulated by ubiquitination associated with the
E3 ligase TRIM72, which targets both the receptor and its associated scaffold protein insulin receptor
substrate 1 (IRS1) for degradation [161]. More recently, the E3 ligase MARCH1 was also shown to
diminish IR surface expression through the induction of ubiquitin-mediated degradation [162]. In a
similar manner to the effect of UBA1 on basal but not ligand-activated VEGFR2, MARCH1 impacts
upon only basal IR surface expression. This may represent a method of fine-tuning the level
of receptor available for engagement by ligand. IGF-1R modification is linked to a number of
E3 enzymes including c-Cbl [163], Nedd4 [164] and Mdm2 [165]. Interestingly, ubiquitination of
IGF-1R by Mdm2 occurs under low IGF-1 conditions but switches to dependence on c-Cbl at high
IGF-1 levels. Both c-Cbl and Mdm2 catalyze IGF-1R ubiquitination at different sites; furthermore,
Mdm2 specifies IGF-1R modification by attachment of K63-linked polyubiquitin chains, whereas
c-Cbl mediates K48-linked polyubiquitin chain attachment [163]. Such biochemical modifications
are reflected in differential endocytic routing of IGF-1R with Mdm2 regulation associated with CDE,
whereas Cbl is associated with CIE. Importantly, Mdm2 regulation of IGF-1R is associated with
proteasome-mediated degradation [165], which further supports a role for K63-linked polyubiquitin
chains in delivering substrates to the 26S proteasome [118]. IGF-1R modification by another E3
enzyme, Nedd4, in association with Grb10 leads to endocytosis, lysosomal degradation and eventual
down-regulation of signal transduction events [166]. Here, the Nedd4/Grb10 complex is associated
with multi-monoubiquitination of IGF-1R. There is also some evidence that Nedd4, Grb10 and ESCRT-0
have complex regulatory roles in VEGFR2 modification, trafficking and proteolysis [167,168].
8. RTK De-Ubiquitination
De-ubiquitinases (DUBs) represent a class of proteases that cleave ubiquitin or ubiquitin-like
modifiers from attachment to substrate proteins. The DUB superfamily comprises ~120 genes that
can be further classified into seven groups, based on the primary sequence of the catalytic domain.
The largest DUB group comprises the ubiquitin-specific processing proteases (USPs), and is made up
of 56 members. These proteins contain a conserved core USP domain, a Cys-X-X-Cys zinc-binding motif
and the catalytic cysteine residue, which classifies this as a cysteine protease [169]. Other DUB cysteine
proteases include the ovarian tumour (OTU) group, which contains 16 active gene products [170]
and the inactive FAM105a member. The group of ubiquitin C-terminal hydrolase (UCH) cysteine
proteases comprises four members with little sequence conservation and catalytic domains ranging
from 223 to 729 amino acids. The group of Machado-Josephin domain (MJD) DUBs has 4 members
that contain a conserved catalytic Josephin domain [171].
A more recently identified and unique DUB group is the motif interacting with novel
ubiquitin-containing novel deubiquitinase family (MINDY) with at least four members [172].
Structural studies show that MINDY enzymes have conserved cysteine and proximal histidine residues
that enable nucleophilic attack on the ubiquitin and ubiquitin-like substrates, although the third
member of the canonical catalytic triad remains to be identified [172]. The DUB group of the monocyte
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chemotactic protein-inducible proteins (MCPIPs) has at least four members [173] linked to immune
regulation. These zinc-finger containing enzymes reduce cellular ubiquitination but are inhibited by the
cysteine protease inhibitor N-ethylmaleiimide [174]. The group of Jab1/Pab1/MPN domain-associated
metalloisopeptidase (JAMM) DUBs has at least 12 members, which are zinc metalloproteases, and thus
distinct from the DUB cysteine proteases. There is also a group of SUMO-specific proteases with at least
8 members, including ubiquitin-specific protease-like 1 (USPL1), SUMO/sentrin specific proteases
(SENP) or desumoylating isopeptidases (DESI).
The removal of ubiquitin and ubiquitin-like modifications on target substrates by DUBs enables
re-use of cellular factors, obviating the need for new protein synthesis. Control of DUB activity is thus
an essential feature of cellular regulation, enabling the re-activation or re-use of proteins. De novo
synthesis of ubiquitin produces either polymeric forms or monoubiquitin precursors fused to ribosomal
proteins, rather than free ubiquitin. Both precursor forms require processing by DUBs to release single
ubiquitin units within the cell [175]. Recent evidence suggests that monoubiquitin release from its
precursors is mediated predominantly by five main DUBs: ubiquitin thioesterase otulin, UCHL3, USP5,
USP7 and USP9X [176], although each has multiple substrates that can be targeted for deubiquitination
to maintain the free ubiquitin pool. Removal of ubiquitin from a target protein from substrates such
as ubiquitinated RTKs allows a new level of regulation of signal transduction that further impacts
on cellular responses associated with RTK function. DUBs have specificity for polyubiquitin chain
cleavage [177–179]. Both recycling and degradation pathways are regulated by ubiquitination [128],
with polyubiquitin chain addition to target substrates strongly linked to proteolysis [180]. DUB activity
thus controls RTK expression and provides a mechanism by which the activated and ubiquitinated
RTK can be redirected away from the degradation pathway towards a return to the plasma membrane.
As DUB activity can significantly affect cellular processes that could lead to a variety of pathologies,
these enzymes have received attention as therapeutic targets [181].
A reverse genetics screen of human DUBs involved in EGFR regulation has identified an
important role for USP18 [182]. Loss of USP18 inhibits cell proliferation and increases apoptosis [183].
However, USP18 regulates EGFR mRNA translation of the EGFR rather than trafficking and
proteolysis [183]. The JAMM member, AMSH, is implicated in regulating EGFR de-ubiquitination
on endosomes [184]; furthermore, AMSH interacts with components of the ESCRT-III complex [185].
A more recent siRNA screen has identified a number of DUBs that significantly modulate EGFR
levels and degradation kinetics [186]. USP9X was a key factor identified from this screen, although it
does not directly target EGFR itself, but instead cleaves ubiquitin from endocytic accessory proteins
including Eps15. Deubiquitination of TrkB by the DUB UCHL1 has been reported, which maintains
expression of the receptor on the cell surface [187]. Loss of UCHL1 diminished TrkB expression at the
plasma membrane and programmed its trafficking to the degradation pathway, leading to abrogated
RTK signaling.
Another DUB enzyme, USP8, functions similarly to target Eps15 [188]. Transgenic mice with
conditional USP8 inactivation develop fatal liver failure associated with the marked downregulation
of several RTKs including EGFR, c-Met and ErbB3 [189]. USP8 has been demonstrated to be
important in the regulation of c-Met levels indirectly through regulation of leucine-rich repeats
and immunoglobulin-like domains 1 protein, LRIG1 [190]. Ubiquitinated LRIG1 recruits c-Met to
lysosomes for degradation; reduction in LRIG1 ubiquitination by USP8 depletion or inactivation thus
enables c-Met levels and functionality to be maintained. USP8 can form complexes with the ESCRT-0
subunit STAM on endosomes, stimulating de-ubiquitination of EGFR on endosomes, and promoting
EGFR endosome-to-plasma membrane recycling [191]. Impairment of USP8 activity has significant
implications, with USP8 mutations that increase catalytic activity promoting de-ubiquitination of
EGFR and increased sensitivity to EGF and development of Cushing’s disease [192]. A recent study
has implicated USP8 requirement in VEGFR2 de-ubiquitination and recycling [193]. Although other
DUBs are likely to have important roles in RTK de-ubiquitination, the majority of recent studies have
identified USP8 as a major therapeutic target in many disease states [194,195].
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9. Conclusions
The RTKs represent a diverse group of families that propagate signals derived from binding their
cognate ligands via transduction along a milieu of intracellular signaling pathways. These circuits
enable the sensing of changes in the extracellular environment (e.g., growth factor levels) and
the translating of such information into appropriate cellular responses. RTKs share common
regulatory mechanisms that control cellular sensitivity to diverse soluble and membrane-bound
ligands. Whilst ubiquitination has a well-documented role in RTK endocytosis, and thus influences
cell surface RTK levels, a deeper understanding of the underlying machinery that controls RTK
post-translational modification and distribution is needed. Indeed, it is evident that RTK ubiquitination
does not simply act as a simple signal for lysosomal degradation, but modulates the balance
between the rate of RTK synthesis, recycling and degradation in different intracellular compartments.
Moreover, attachment of different ubiquitin tags to a specific RTK opens up the possibility of
modulating different signal transduction pathways which are influenced by RTK residence within
a specific location. Ubiquitin-modifying enzymes comprising E1, E2, E3 and DUB families may be
further positioned at these different locations to influence RTK modification, turnover and distribution.
Such effects would invariably impact on the steady-state or basal RTK levels at the plasma membrane,
thus dictating RTK availability for sensing exogenous circulating ligand(s). Such ubiquitin-modifying
enzymes are increasingly important therapeutic targets for targeting RTK function in diverse disease
states including cancer, heart disease and diabetes.
Acknowledgments: We thank the Endothelial Cell Biology Unit members for their help and advice. This work
was supported by British Heart Foundation project grant PG/16/86/32474 to S.P., I.C.Z. and M.A.H.
Author Contributions: W.R.C. and S.P. planned the manuscript; W.R.C. wrote the first draft of the manuscript;
S.P., C.P.-M., B.R.-T., M.A.H. and I.C.Z. edited and commented on the manuscript.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Robinson, D.R.; Wu, Y.M.; Lin, S.F. The protein tyrosine kinase family of the human genome. Oncogene 2000,
19, 5548–5557. [CrossRef] [PubMed]
2. Blume-Jensen, P.; Hunter, T. Oncogenic kinase signaling. Nature 2001, 411, 355–365. [CrossRef] [PubMed]
3. Lemmon, M.A.; Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 2010, 141, 1117–1134.
[CrossRef] [PubMed]
4. Marino-Buslje, C.; Mizuguchi, K.; Siddle, K.; Blundell, T.L. A third fibronectin type iii domain in the
extracellular region of the insulin receptor family. FEBS Lett. 1998, 441, 331–336. [CrossRef]
5. Tuzi, N.L.; Gullick, W.J. Eph, the largest known family of putative growth factor receptors. Br. J. Cancer 1994,
69, 417–421. [CrossRef] [PubMed]
6. Garrett, T.P.; McKern, N.M.; Lou, M.; Frenkel, M.J.; Bentley, J.D.; Lovrecz, G.O.; Elleman, T.C.; Cosgrove, L.J.;
Ward, C.W. Crystal structure of the first three domains of the type-1 insulin-like growth factor receptor.
Nature 1998, 394, 395–399. [CrossRef] [PubMed]
7. Ward, C.W.; Hoyne, P.A.; Flegg, R.H. Insulin and epidermal growth factor receptors contain the cysteine
repeat motif found in the tumor necrosis factor receptor. Proteins 1995, 22, 141–153. [CrossRef] [PubMed]
8. Grassot, J.; Gouy, M.; Perriere, G.; Mouchiroud, G. Origin and molecular evolution of receptor tyrosine
kinases with immunoglobulin-like domains. Mol. Biol. Evol. 2006, 23, 1232–1241. [CrossRef] [PubMed]
9. Windisch, J.M.; Auer, B.; Marksteiner, R.; Lang, M.E.; Schneider, R. Specific neurotrophin binding to
leucine-rich motif peptides of trka and trkb. FEBS Lett. 1995, 374, 125–129. [CrossRef]
10. Reshetnyak, A.V.; Murray, P.B.; Shi, X.; Mo, E.S.; Mohanty, J.; Tome, F.; Bai, H.; Gunel, M.; Lax, I.;
Schlessinger, J. Augmentor alpha and beta (fam150) are ligands of the receptor tyrosine kinases alk and ltk:
Hierarchy and specificity of ligand-receptor interactions. Proc. Natl. Acad. Sci. USA 2015, 112, 15862–15867.
[CrossRef] [PubMed]
Cells 2018, 7, 22 15 of 24
11. Manni, S.; Kisko, K.; Schleier, T.; Missimer, J.; Ballmer-Hofer, K. Functional and structural characterization of
the kinase insert and the carboxy terminal domain in vegf receptor 2 activation. FASEB J. 2014, 28, 4914–4923.
[CrossRef] [PubMed]
12. Sarabipour, S.; Hristova, K. Mechanism of fgf receptor dimerization and activation. Nat. Commun. 2016, 7, 10262.
[CrossRef] [PubMed]
13. Jahangiri, A.; Nguyen, A.; Chandra, A.; Sidorov, M.K.; Yagnik, G.; Rick, J.; Han, S.W.; Chen, W.; Flanigan, P.M.;
Schneidman-Duhovny, D.; et al. Cross-activating c-met/beta1 integrin complex drives metastasis and
invasive resistance in cancer. Proc. Natl. Acad. Sci. USA 2017, 114, E8685–E8694. [PubMed]
14. Weiss, F.U.; Daub, H.; Ullrich, A. Novel mechanisms of rtk signal generation. Curr. Opin. Genet. Dev. 1997, 7,
80–86. [CrossRef]
15. Hubbard, S.R.; Miller, W.T. Receptor tyrosine kinases: Mechanisms of activation and signaling. Curr. Opin.
Cell Biol. 2007, 19, 117–123. [CrossRef] [PubMed]
16. Volinsky, N.; Kholodenko, B.N. Complexity of receptor tyrosine kinase signal processing. Cold Spring Harbor
Perspect. Biol. 2013, 5, a009043. [CrossRef] [PubMed]
17. Hsieh, M.Y.; Yang, S.; Raymond-Stinz, M.A.; Edwards, J.S.; Wilson, B.S. Spatio-temporal modeling of
signaling protein recruitment to egfr. BMC Syst. Biol. 2010, 4, 57. [CrossRef] [PubMed]
18. Ott, C.M.; Lingappa, V.R. Integral membrane protein biosynthesis: Why topology is hard to predict. J. Cell Sci.
2002, 115, 2003–2009. [PubMed]
19. Scharaw, S.; Iskar, M.; Ori, A.; Boncompain, G.; Laketa, V.; Poser, I.; Lundberg, E.; Perez, F.; Beck, M.;
Bork, P.; et al. The endosomal transcriptional regulator rnf11 integrates degradation and transport of egfr. J.
Cell Biol. 2016, 215, 543–558. [CrossRef] [PubMed]
20. Crepaldi, T.; Pollack, A.L.; Prat, M.; Zborek, A.; Mostov, K.; Comoglio, P.M. Targeting of the sf/hgf receptor
to the basolateral domain of polarized epithelial cells. J. Cell Biol. 1994, 125, 313–320. [CrossRef] [PubMed]
21. Hobert, M.E.; Kil, S.J.; Medof, M.E.; Carlin, C.R. The cytoplasmic juxtamembrane domain of the epidermal
growth factor receptor contains a novel autonomous basolateral sorting determinant. J. Biol. Chem. 1997, 272,
32901–32909. [CrossRef] [PubMed]
22. Mittar, S.; Ulyatt, C.; Howell, G.J.; Bruns, A.F.; Zachary, I.; Walker, J.H.; Ponnambalam, S. Vegfr1 receptor
tyrosine kinase localization to the golgi apparatus is calcium-dependent. Exp. Cell Res. 2009, 315, 877–889.
[CrossRef] [PubMed]
23. Manickam, V.; Tiwari, A.; Jung, J.J.; Bhattacharya, R.; Goel, A.; Mukhopadhyay, D.; Choudhury, A.
Regulation of vascular endothelial growth factor receptor 2 trafficking and angiogenesis by golgi localized
t-snare syntaxin 6. Blood 2011, 117, 1425–1435. [CrossRef] [PubMed]
24. Tiwari, A.; Jung, J.J.; Inamdar, S.M.; Nihalani, D.; Choudhury, A. The myosin motor myo1c is required for
vegfr2 delivery to the cell surface and for angiogenic signaling. Am. J. Physiol. Heart Circ. Physiol. 2013, 304,
H687–H696. [CrossRef] [PubMed]
25. Yamada, K.H.; Nakajima, Y.; Geyer, M.; Wary, K.K.; Ushio-Fukai, M.; Komarova, Y.; Malik, A.B.
Kif13b regulates angiogenesis through golgi to plasma membrane trafficking of vegfr2. J. Cell Sci. 2014, 127,
4518–4530. [CrossRef] [PubMed]
26. Chen, B.; Zhao, L.; Li, X.; Ji, Y.S.; Li, N.; Xu, X.F.; Chen, Z.Y. Syntaxin 8 modulates the post-synthetic
trafficking of the trka receptor and inflammatory pain transmission. J. Biol. Chem. 2014, 289, 19556–19569.
[CrossRef] [PubMed]
27. Du, Y.; Shen, J.; Hsu, J.L.; Han, Z.; Hsu, M.C.; Yang, C.C.; Kuo, H.P.; Wang, Y.N.; Yamaguchi, H.;
Miller, S.A.; et al. Syntaxin 6-mediated golgi translocation plays an important role in nuclear functions of
egfr through microtubule-dependent trafficking. Oncogene 2014, 33, 756–770. [CrossRef] [PubMed]
28. Warren, C.M.; Ziyad, S.; Briot, A.; Der, A.; Iruela-Arispe, M.L. A ligand-independent vegfr2 signaling
pathway limits angiogenic responses in diabetes. Sci. Signal. 2014, 7, ra1. [CrossRef] [PubMed]
29. Maghsoudlou, A.; Meyer, R.D.; Rezazadeh, K.; Arafa, E.; Pudney, J.; Hartsough, E.; Rahimi, N. Rnf121 inhibits
angiogenic growth factor signaling by restricting cell surface expression of vegfr-2. Traffic 2016, 17, 289–300.
[CrossRef] [PubMed]
30. Jastrzebski, K.; Zdzalik-Bielecka, D.; Maminska, A.; Kalaidzidis, Y.; Hellberg, C.; Miaczynska, M.
Multiple routes of endocytic internalization of pdgfrbeta contribute to pdgf-induced stat3 signaling.
J. Cell Sci. 2017, 130, 577–589. [CrossRef] [PubMed]
Cells 2018, 7, 22 16 of 24
31. Vieira, A.V.; Lamaze, C.; Schmid, S.L. Control of egf receptor signaling by clathrin-mediated endocytosis.
Science 1996, 274, 2086–2089. [CrossRef] [PubMed]
32. Sigismund, S.; Argenzio, E.; Tosoni, D.; Cavallaro, E.; Polo, S.; Di Fiore, P.P. Clathrin-mediated internalization
is essential for sustained egfr signaling but dispensable for degradation. Dev. Cell 2008, 15, 209–219.
[CrossRef] [PubMed]
33. Tanaka, T.; Zhou, Y.; Ozawa, T.; Okizono, R.; Banba, A.; Yamamura, T.; Oga, E.; Muraguchi, A.; Sakurai, H.
Ligand-activated epidermal growth factor receptor (egfr) signaling governs endocytic trafficking of
unliganded receptor monomers by non-canonical phosphorylation. J. Biol. Chem. 2018, 293, 2288–2301.
[CrossRef] [PubMed]
34. Ewan, L.C.; Jopling, H.M.; Jia, H.; Mittar, S.; Bagherzadeh, A.; Howell, G.J.; Walker, J.H.; Zachary, I.C.;
Ponnambalam, S. Intrinsic tyrosine kinase activity is required for vascular endothelial growth factor receptor
2 ubiquitination, sorting and degradation in endothelial cells. Traffic 2006, 7, 1270–1282. [CrossRef] [PubMed]
35. Lampugnani, M.G.; Orsenigo, F.; Gagliani, M.C.; Tacchetti, C.; Dejana, E. Vascular endothelial cadherin
controls vegfr-2 internalization and signaling from intracellular compartments. J. Cell Biol. 2006, 174, 593–604.
[CrossRef] [PubMed]
36. Bruns, A.F.; Herbert, S.P.; Odell, A.F.; Jopling, H.M.; Hooper, N.M.; Zachary, I.C.; Walker, J.H.;
Ponnambalam, S. Ligand-stimulated vegfr2 signaling is regulated by co-ordinated trafficking and proteolysis.
Traffic 2010, 11, 161–174. [CrossRef] [PubMed]
37. Fearnley, G.W.; Smith, G.A.; Abdul-Zani, I.; Yuldasheva, N.; Mughal, N.A.; Homer-Vanniasinkam, S.;
Kearney, M.T.; Zachary, I.C.; Tomlinson, D.C.; Harrison, M.A.; et al. Vegf-a isoforms program differential
vegfr2 signal transduction, trafficking and proteolysis. Biol. Open 2016, 5, 571–583. [CrossRef] [PubMed]
38. Delos Santos, R.C.; Bautista, S.; Lucarelli, S.; Bone, L.N.; Dayam, R.M.; Abousawan, J.; Botelho, R.J.;
Antonescu, C.N. Selective regulation of clathrin-mediated epidermal growth factor receptor signaling
and endocytosis by phospholipase c and calcium. Mol. Biol. Cell 2017, 28, 2802–2818. [CrossRef] [PubMed]
39. Bogdanovic, E.; Coombs, N.; Dumont, D.J. Oligomerized tie2 localizes to clathrin-coated pits in response to
angiopoietin-1. Histochem. Cell Biol. 2009, 132, 225–237. [CrossRef] [PubMed]
40. Wilde, A.; Beattie, E.C.; Lem, L.; Riethof, D.A.; Liu, S.H.; Mobley, W.C.; Soriano, P.; Brodsky, F.M. Egf receptor
signaling stimulates src kinase phosphorylation of clathrin, influencing clathrin redistribution and egf
uptake. Cell 1999, 96, 677–687. [CrossRef]
41. Goh, L.K.; Huang, F.; Kim, W.; Gygi, S.; Sorkin, A. Multiple mechanisms collectively regulate
clathrin-mediated endocytosis of the epidermal growth factor receptor. J. Cell Biol. 2010, 189, 871–883.
[CrossRef] [PubMed]
42. Jiang, X.; Huang, F.; Marusyk, A.; Sorkin, A. Grb2 regulates internalization of egf receptors through
clathrin-coated pits. Mol. Biol. Cell 2003, 14, 858–870. [CrossRef] [PubMed]
43. Ioannou, M.S.; Kulasekaran, G.; Fotouhi, M.; Morein, J.J.; Han, C.; Tse, S.; Nossova, N.; Han, T.; Mannard, E.;
McPherson, P.S. Intersectin-s interaction with dennd2b facilitates recycling of epidermal growth factor
receptor. EMBO Rep. 2017, 18, 2119–2130. [CrossRef] [PubMed]
44. Puri, C.; Tosoni, D.; Comai, R.; Rabellino, A.; Segat, D.; Caneva, F.; Luzzi, P.; Di Fiore, P.P.; Tacchetti, C.
Relationships between egfr signaling-competent and endocytosis-competent membrane microdomains.
Mol. Biol. Cell 2005, 16, 2704–2718. [CrossRef] [PubMed]
45. Rappoport, J.Z.; Simon, S.M. Endocytic trafficking of activated egfr is ap-2 dependent and occurs through
preformed clathrin spots. J. Cell Sci. 2009, 122, 1301–1305. [CrossRef] [PubMed]
46. Sigismund, S.; Woelk, T.; Puri, C.; Maspero, E.; Tacchetti, C.; Transidico, P.; Di Fiore, P.P.; Polo, S.
Clathrin-independent endocytosis of ubiquitinated cargos. Proc. Natl. Acad. Sci. USA 2005, 102, 2760–2765.
[CrossRef] [PubMed]
47. Caldieri, G.; Barbieri, E.; Nappo, G.; Raimondi, A.; Bonora, M.; Conte, A.; Verhoef, L.; Confalonieri, S.;
Malabarba, M.G.; Bianchi, F.; et al. Reticulon 3-dependent er-pm contact sites control egfr nonclathrin
endocytosis. Science 2017, 356, 617–624. [CrossRef] [PubMed]
48. Basagiannis, D.; Zografou, S.; Murphy, C.; Fotsis, T.; Morbidelli, L.; Ziche, M.; Bleck, C.; Mercer, J.;
Christoforidis, S. Vegf induces signaling and angiogenesis by directing vegfr2 internalisation through
macropinocytosis. J. Cell Sci. 2016, 129, 4091–4104. [PubMed]
Cells 2018, 7, 22 17 of 24
49. Yamabhai, M.; Anderson, R.G. Second cysteine-rich region of epidermal growth factor receptor contains
targeting information for caveolae/rafts. J. Biol. Chem. 2002, 277, 24843–24846. [CrossRef] [PubMed]
50. Ikeda, S.; Ushio-Fukai, M.; Zuo, L.; Tojo, T.; Dikalov, S.; Patrushev, N.A.; Alexander, R.W. Novel role of
arf6 in vascular endothelial growth factor-induced signaling and angiogenesis. Circ. Res. 2005, 96, 467–475.
[CrossRef] [PubMed]
51. Yamaguchi, T.; Lu, C.; Ida, L.; Yanagisawa, K.; Usukura, J.; Cheng, J.; Hotta, N.; Shimada, Y.; Isomura, H.;
Suzuki, M.; et al. Ror1 sustains caveolae and survival signaling as a scaffold of cavin-1 and caveolin-1.
Nat. Commun. 2016, 7, 10060. [CrossRef] [PubMed]
52. Mastick, C.C.; Brady, M.J.; Saltiel, A.R. Insulin stimulates the tyrosine phosphorylation of caveolin. J. Cell Biol.
1995, 129, 1523–1531. [CrossRef] [PubMed]
53. Labrecque, L.; Royal, I.; Surprenant, D.S.; Patterson, C.; Gingras, D.; Beliveau, R. Regulation of vascular
endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol. Mol. Biol. Cell
2003, 14, 334–347. [CrossRef] [PubMed]
54. Orlichenko, L.; Huang, B.; Krueger, E.; McNiven, M.A. Epithelial growth factor-induced phosphorylation of
caveolin 1 at tyrosine 14 stimulates caveolae formation in epithelial cells. J. Biol. Chem. 2006, 281, 4570–4579.
[CrossRef] [PubMed]
55. Verma, N.; Keinan, O.; Selitrennik, M.; Karn, T.; Filipits, M.; Lev, S. Pyk2 sustains endosomal-derived receptor
signaling and enhances epithelial-to-mesenchymal transition. Nat. Commun. 2015, 6, 6064. [CrossRef]
[PubMed]
56. Taub, N.; Teis, D.; Ebner, H.L.; Hess, M.W.; Huber, L.A. Late endosomal traffic of the epidermal growth factor
receptor ensures spatial and temporal fidelity of mitogen-activated protein kinase signaling. Mol. Biol. Cell
2007, 18, 4698–4710. [CrossRef] [PubMed]
57. Laviolette, L.A.; Mermoud, J.; Calvo, I.A.; Olson, N.; Boukhali, M.; Steinlein, O.K.; Roider, E.; Sattler, E.C.;
Huang, D.; Teh, B.T.; et al. Negative regulation of egfr signaling by the human folliculin tumour suppressor
protein. Nat. Commun. 2017, 8, 15866. [CrossRef] [PubMed]
58. Kermorgant, S.; Parker, P.J. Receptor trafficking controls weak signal delivery: A strategy used by c-met for
stat3 nuclear accumulation. J. Cell Biol. 2008, 182, 855–863. [CrossRef] [PubMed]
59. Menard, L.; Parker, P.J.; Kermorgant, S. Receptor tyrosine kinase c-met controls the cytoskeleton from
different endosomes via different pathways. Nat. Commun. 2014, 5, 3907. [CrossRef] [PubMed]
60. Wang, Y.; Pennock, S.D.; Chen, X.; Kazlauskas, A.; Wang, Z. Platelet-derived growth factor receptor-mediated
signal transduction from endosomes. J. Biol. Chem. 2004, 279, 8038–8046. [CrossRef] [PubMed]
61. Kofler, N.; Corti, F.; Rivera-Molina, F.; Deng, Y.; Toomre, D.; Simons, M. The rab-effector protein rabep2
regulates endosomal trafficking to mediate vascular endothelial growth factor receptor-2 (vegfr2)-dependent
signaling. J. Biol. Chem. 2018. [CrossRef] [PubMed]
62. Acconcia, F.; Sigismund, S.; Polo, S. Ubiquitin in trafficking: The network at work. Exp. Cell Res. 2009, 315,
1610–1618. [CrossRef] [PubMed]
63. Girnita, L.; Takahashi, S.I.; Crudden, C.; Fukushima, T.; Worrall, C.; Furuta, H.; Yoshihara, H.; Hakuno, F.;
Girnita, A. Chapter seven-when phosphorylation encounters ubiquitination: A balanced perspective on
igf-1r signaling. Prog. Mol. Biol. Transl. Sci. 2016, 141, 277–311. [PubMed]
64. Smith, G.A.; Tomlinson, D.C.; Harrison, M.A.; Ponnambalam, S. Chapter eight-ubiquitin-mediated regulation
of cellular responses to vascular endothelial growth factors. Prog. Mol. Biol. Transl. Sci. 2016, 141, 313–338.
[PubMed]
65. Smith, G.A.; Fearnley, G.W.; Abdul-Zani, I.; Wheatcroft, S.B.; Tomlinson, D.C.; Harrison, M.A.;
Ponnambalam, S. Ubiquitination of basal vegfr2 regulates signal transduction and endothelial function.
Biol. Open 2017, 6, 1404–1415. [CrossRef] [PubMed]
66. Sorkin, A.; Goh, L.K. Endocytosis and intracellular trafficking of erbbs. Exp. Cell Res. 2008, 314, 3093–3106.
[CrossRef] [PubMed]
67. Gucwa, A.L.; Brown, D.A. Uim domain-dependent recruitment of the endocytic adaptor protein eps15 to
ubiquitin-enriched endosomes. BMC Cell Biol. 2014, 15, 34. [CrossRef] [PubMed]
68. Lund, P.K.; Moats-Staats, B.M.; Simmons, J.G.; Hoyt, E.; D’Ercole, A.J.; Martin, F.; Van Wyk, J.J.
Nucleotide sequence analysis of a cdna encoding human ubiquitin reveals that ubiquitin is synthesized as a
precursor. J. Biol. Chem. 1985, 260, 7609–7613. [PubMed]
Cells 2018, 7, 22 18 of 24
69. Wiborg, O.; Pedersen, M.S.; Wind, A.; Berglund, L.E.; Marcker, K.A.; Vuust, J. The human ubiquitin multigene
family: Some genes contain multiple directly repeated ubiquitin coding sequences. EMBO J. 1985, 4, 755–759.
[PubMed]
70. McGrath, J.P.; Jentsch, S.; Varshavsky, A. Uba 1: An essential yeast gene encoding ubiquitin-activating
enzyme. EMBO J. 1991, 10, 227–236. [PubMed]
71. Pelzer, C.; Kassner, I.; Matentzoglu, K.; Singh, R.K.; Wollscheid, H.P.; Scheffner, M.; Schmidtke, G.;
Groettrup, M. Ube1l2, a novel e1 enzyme specific for ubiquitin. J. Biol. Chem. 2007, 282, 23010–23014.
[CrossRef] [PubMed]
72. Desterro, J.M.; Rodriguez, M.S.; Kemp, G.D.; Hay, R.T. Identification of the enzyme required for activation of
the small ubiquitin-like protein sumo-1. J. Biol. Chem. 1999, 274, 10618–10624. [CrossRef] [PubMed]
73. Gong, L.; Yeh, E.T. Identification of the activating and conjugating enzymes of the nedd8 conjugation
pathway. J. Biol. Chem. 1999, 274, 12036–12042. [CrossRef] [PubMed]
74. Van der Veen, A.G.; Schorpp, K.; Schlieker, C.; Buti, L.; Damon, J.R.; Spooner, E.; Ploegh, H.L.; Jentsch, S.
Role of the ubiquitin-like protein urm1 as a noncanonical lysine-directed protein modifier. Proc. Natl. Acad.
Sci. USA 2011, 108, 1763–1770. [CrossRef] [PubMed]
75. Komatsu, M.; Chiba, T.; Tatsumi, K.; Iemura, S.; Tanida, I.; Okazaki, N.; Ueno, T.; Kominami, E.; Natsume, T.;
Tanaka, K. A novel protein-conjugating system for ufm1, a ubiquitin-fold modifier. EMBO J. 2004, 23,
1977–1986. [CrossRef] [PubMed]
76. Yuan, W.; Krug, R.M. Influenza b virus ns1 protein inhibits conjugation of the interferon (ifn)-induced
ubiquitin-like isg15 protein. EMBO J. 2001, 20, 362–371. [CrossRef] [PubMed]
77. Huang, D.T.; Miller, D.W.; Mathew, R.; Cassell, R.; Holton, J.M.; Roussel, M.F.; Schulman, B.A. A unique
e1-e2 interaction required for optimal conjugation of the ubiquitin-like protein nedd8. Nat. Struct. Mol. Biol.
2004, 11, 927–935. [CrossRef] [PubMed]
78. Mizushima, N.; Noda, T.; Yoshimori, T.; Tanaka, Y.; Ishii, T.; George, M.D.; Klionsky, D.J.; Ohsumi, M.;
Ohsumi, Y. A protein conjugation system essential for autophagy. Nature 1998, 395, 395–398. [CrossRef]
[PubMed]
79. Oweis, W.; Padala, P.; Hassouna, F.; Cohen-Kfir, E.; Gibbs, D.R.; Todd, E.A.; Berndsen, C.E.; Wiener, R.
Trans-binding mechanism of ubiquitin-like protein activation revealed by a uba5-ufm1 complex. Cell Rep.
2016, 16, 3113–3120. [CrossRef] [PubMed]
80. Mashahreh, B.; Hassouna, F.; Soudah, N.; Cohen-Kfir, E.; Strulovich, R.; Haitin, Y.; Wiener, R. Trans-binding
of ufm1 to uba5 stimulates uba5 homodimerization and atp binding. FASEB J. 2018, fj201701057R. [CrossRef]
[PubMed]
81. Cook, B.W.; Shaw, G.S. Architecture of the catalytic hpn motif is conserved in all e2 conjugating enzymes.
Biochem. J. 2012, 445, 167–174. [CrossRef] [PubMed]
82. Wu, P.Y.; Hanlon, M.; Eddins, M.; Tsui, C.; Rogers, R.S.; Jensen, J.P.; Matunis, M.J.; Weissman, A.M.;
Wolberger, C.; Pickart, C.M. A conserved catalytic residue in the ubiquitin-conjugating enzyme family.
EMBO J. 2003, 22, 5241–5250. [CrossRef] [PubMed]
83. Morreale, F.E.; Walden, H. Types of ubiquitin ligases. Cell 2016, 165, 248. [CrossRef] [PubMed]
84. Li, W.; Bengtson, M.H.; Ulbrich, A.; Matsuda, A.; Reddy, V.A.; Orth, A.; Chanda, S.K.; Batalov, S.; Joazeiro, C.A.
Genome-wide and functional annotation of human e3 ubiquitin ligases identifies mulan, a mitochondrial e3
that regulates the organelle’s dynamics and signaling. PLoS ONE 2008, 3, e1487. [CrossRef] [PubMed]
85. Huibregtse, J.M.; Scheffner, M.; Beaudenon, S.; Howley, P.M. A family of proteins structurally and
functionally related to the e6-ap ubiquitin-protein ligase. Proc. Natl. Acad. Sci. USA 1995, 92, 5249.
[CrossRef] [PubMed]
86. Kim, H.C.; Steffen, A.M.; Oldham, M.L.; Chen, J.; Huibregtse, J.M. Structure and function of a hect domain
ubiquitin-binding site. EMBO Rep. 2011, 12, 334–341. [CrossRef] [PubMed]
87. Hatakeyama, S.; Nakayama, K.I. U-box proteins as a new family of ubiquitin ligases. Biochem. Biophys.
Res. Commun. 2003, 302, 635–645. [CrossRef]
88. Kamadurai, H.B.; Souphron, J.; Scott, D.C.; Duda, D.M.; Miller, D.J.; Stringer, D.; Piper, R.C.; Schulman, B.A.
Insights into ubiquitin transfer cascades from a structure of a ubch5b approximately ubiquitin-hect(nedd4l)
complex. Mol. Cell 2009, 36, 1095–1102. [CrossRef] [PubMed]
Cells 2018, 7, 22 19 of 24
89. Deshaies, R.J.; Joazeiro, C.A. Ring domain e3 ubiquitin ligases. Ann. Rev. Biochem. 2009, 78, 399–434.
[CrossRef] [PubMed]
90. Pruneda, J.N.; Littlefield, P.J.; Soss, S.E.; Nordquist, K.A.; Chazin, W.J.; Brzovic, P.S.; Klevit, R.E. Structure of
an e3:E2~ub complex reveals an allosteric mechanism shared among ring/u-box ligases. Mol. Cell 2012, 47,
933–942. [CrossRef] [PubMed]
91. Kirisako, T.; Kamei, K.; Murata, S.; Kato, M.; Fukumoto, H.; Kanie, M.; Sano, S.; Tokunaga, F.; Tanaka, K.;
Iwai, K. A ubiquitin ligase complex assembles linear polyubiquitin chains. EMBO J. 2006, 25, 4877–4887.
[CrossRef] [PubMed]
92. Guzzo, C.M.; Berndsen, C.E.; Zhu, J.; Gupta, V.; Datta, A.; Greenberg, R.A.; Wolberger, C.; Matunis, M.J.
Rnf4-dependent hybrid sumo-ubiquitin chains are signals for rap80 and thereby mediate the recruitment of
brca1 to sites of DNA damage. Sci. Signal. 2012, 5, ra88. [CrossRef] [PubMed]
93. Schmidt, C.K.; Galanty, Y.; Sczaniecka-Clift, M.; Coates, J.; Jhujh, S.; Demir, M.; Cornwell, M.; Beli, P.;
Jackson, S.P. Systematic e2 screening reveals a ube2d-rnf138-ctip axis promoting DNA repair. Nat. Cell Biol.
2015, 17, 1458–1470. [CrossRef] [PubMed]
94. Han, D.; Liang, J.; Lu, Y.; Xu, L.; Miao, S.; Lu, L.Y.; Song, W.; Wang, L. Ubiquitylation of rad51d mediated
by e3 ligase rnf138 promotes the homologous recombination repair pathway. PLoS ONE 2016, 11, e0155476.
[CrossRef] [PubMed]
95. Uckelmann, M.; Sixma, T.K. Histone ubiquitination in the DNA damage response. DNA Repair 2017, 56,
92–101. [CrossRef] [PubMed]
96. Wijnhoven, P.; Konietzny, R.; Blackford, A.N.; Travers, J.; Kessler, B.M.; Nishi, R.; Jackson, S.P.
Usp4 auto-deubiquitylation promotes homologous recombination. Mol. Cell 2015, 60, 362–373. [CrossRef]
[PubMed]
97. Beli, P.; Jackson, S.P. Ubiquitin regulates dissociation of DNA repair factors from chromatin. Oncotarget 2015,
6, 14727–14728. [CrossRef] [PubMed]
98. Baranes-Bachar, K.; Levy-Barda, A.; Oehler, J.; Reid, D.A.; Soria-Bretones, I.; Voss, T.C.; Chung, D.; Park, Y.;
Liu, C.; Yoon, J.B.; et al. The ubiquitin e3/e4 ligase ube4a adjusts protein ubiquitylation and accumulation
at sites of DNA damage, facilitating double-strand break repair. Mol. Cell 2018, 69, 866–878. [CrossRef]
[PubMed]
99. Elia, A.E.; Boardman, A.P.; Wang, D.C.; Huttlin, E.L.; Everley, R.A.; Dephoure, N.; Zhou, C.; Koren, I.;
Gygi, S.P.; Elledge, S.J. Quantitative proteomic atlas of ubiquitination and acetylation in the DNA damage
response. Mol. Cell 2015, 59, 867–881. [CrossRef] [PubMed]
100. Gatti, M.; Pinato, S.; Maiolica, A.; Rocchio, F.; Prato, M.G.; Aebersold, R.; Penengo, L. Rnf168 promotes
noncanonical k27 ubiquitination to signal DNA damage. Cell Rep. 2015, 10, 226–238. [CrossRef] [PubMed]
101. Meyer, H.J.; Rape, M. Enhanced protein degradation by branched ubiquitin chains. Cell 2014, 157, 910–921.
[CrossRef] [PubMed]
102. Fei, C.; Li, Z.; Li, C.; Chen, Y.; Chen, Z.; He, X.; Mao, L.; Wang, X.; Zeng, R.; Li, L. Smurf1-mediated
lys29-linked nonproteolytic polyubiquitination of axin negatively regulates wnt/beta-catenin signaling.
Mol. Cell. Biol. 2013, 33, 4095–4105. [CrossRef] [PubMed]
103. Lu, Y.; Lee, B.H.; King, R.W.; Finley, D.; Kirschner, M.W. Substrate degradation by the proteasome:
A single-molecule kinetic analysis. Science 2015, 348, 1250834. [CrossRef] [PubMed]
104. Nathan, J.A.; Kim, H.T.; Ting, L.; Gygi, S.P.; Goldberg, A.L. Why do cellular proteins linked to
k63-polyubiquitin chains not associate with proteasomes? EMBO J. 2013, 32, 552–565. [CrossRef] [PubMed]
105. Liu, C.S.; Yang-Yen, H.F.; Suen, C.S.; Hwang, M.J.; Yen, J.J. Cbl-mediated k63-linked ubiquitination of jak2
enhances jak2 phosphorylation and signal transduction. Sci. Rep. 2017, 7, 4613. [CrossRef] [PubMed]
106. Ohtake, F.; Saeki, Y.; Ishido, S.; Kanno, J.; Tanaka, K. The k48-k63 branched ubiquitin chain regulates
nf-kappab signaling. Mol. Cell 2016, 64, 251–266. [CrossRef] [PubMed]
107. Ohtake, F.; Tsuchiya, H.; Saeki, Y.; Tanaka, K. K63 ubiquitylation triggers proteasomal degradation by
seeding branched ubiquitin chains. Proc. Natl. Acad. Sci. USA 2018, 115, E1401–E1408. [CrossRef] [PubMed]
108. Fiil, B.K.; Damgaard, R.B.; Wagner, S.A.; Keusekotten, K.; Fritsch, M.; Bekker-Jensen, S.; Mailand, N.;
Choudhary, C.; Komander, D.; Gyrd-Hansen, M. Otulin restricts met1-linked ubiquitination to control innate
immune signaling. Mol. Cell 2013, 50, 818–830. [CrossRef] [PubMed]
Cells 2018, 7, 22 20 of 24
109. Dziedzic, S.A.; Su, Z.; Jean Barrett, V.; Najafov, A.; Mookhtiar, A.K.; Amin, P.; Pan, H.; Sun, L.; Zhu, H.;
Ma, A.; et al. Abin-1 regulates ripk1 activation by linking met1 ubiquitylation with lys63 deubiquitylation in
tnf-rsc. Nat. Cell Biol. 2018, 20, 58–68. [CrossRef] [PubMed]
110. Alkan, Z.; Duong, F.L.; Hawkes, W.C. Selenoprotein w controls epidermal growth factor receptor surface
expression, activation and degradation via receptor ubiquitination. Biochim. Biophys. Acta 2015, 1853,
1087–1095. [CrossRef] [PubMed]
111. Haugsten, E.M.; Zakrzewska, M.; Brech, A.; Pust, S.; Olsnes, S.; Sandvig, K.; Wesche, J. Clathrin- and
dynamin-independent endocytosis of fgfr3—Implications for signaling. PLoS ONE 2011, 6, e21708.
[CrossRef] [PubMed]
112. Lanahan, A.A.; Hermans, K.; Claes, F.; Kerley-Hamilton, J.S.; Zhuang, Z.W.; Giordano, F.J.; Carmeliet, P.;
Simons, M. Vegf receptor 2 endocytic trafficking regulates arterial morphogenesis. Dev. Cell 2010, 18, 713–724.
[CrossRef] [PubMed]
113. Lu, Z.; Je, H.S.; Young, P.; Gross, J.; Lu, B.; Feng, G. Regulation of synaptic growth and maturation by a
synapse-associated e3 ubiquitin ligase at the neuromuscular junction. J. Cell Biol. 2007, 177, 1077–1089.
[CrossRef] [PubMed]
114. Arevalo, J.C.; Waite, J.; Rajagopal, R.; Beyna, M.; Chen, Z.Y.; Lee, F.S.; Chao, M.V. Cell survival through trk
neurotrophin receptors is differentially regulated by ubiquitination. Neuron 2006, 50, 549–559. [CrossRef]
[PubMed]
115. Geetha, T.; Jiang, J.; Wooten, M.W. Lysine 63 polyubiquitination of the nerve growth factor receptor trka
directs internalization and signaling. Mol. Cell 2005, 20, 301–312. [CrossRef] [PubMed]
116. Geetha, T.; Wooten, M.W. Trka receptor endolysosomal degradation is both ubiquitin and proteasome
dependent. Traffic 2008, 9, 1146–1156. [CrossRef] [PubMed]
117. Haglund, K.; Sigismund, S.; Polo, S.; Szymkiewicz, I.; Di Fiore, P.P.; Dikic, I. Multiple monoubiquitination of
rtks is sufficient for their endocytosis and degradation. Nat. Cell Biol. 2003, 5, 461–466. [CrossRef] [PubMed]
118. Huang, F.; Zeng, X.; Kim, W.; Balasubramani, M.; Fortian, A.; Gygi, S.P.; Yates, N.A.; Sorkin, A.
Lysine 63-linked polyubiquitination is required for egf receptor degradation. Proc. Natl. Acad. Sci. USA 2013,
110, 15722–15727. [CrossRef] [PubMed]
119. Hofmann, K.; Falquet, L. A ubiquitin-interacting motif conserved in components of the proteasomal and
lysosomal protein degradation systems. Trends Biochem. Sci. 2001, 26, 347–350. [CrossRef]
120. Polo, S.; Sigismund, S.; Faretta, M.; Guidi, M.; Capua, M.R.; Bossi, G.; Chen, H.; De Camilli, P.; Di Fiore, P.P.
A single motif responsible for ubiquitin recognition and monoubiquitination in endocytic proteins. Nature
2002, 416, 451–455. [CrossRef] [PubMed]
121. Barriere, H.; Nemes, C.; Lechardeur, D.; Khan-Mohammad, M.; Fruh, K.; Lukacs, G.L. Molecular basis of
oligoubiquitin-dependent internalization of membrane proteins in mammalian cells. Traffic 2006, 7, 282–297.
[CrossRef] [PubMed]
122. Baldys, A.; Raymond, J.R. Critical role of escrt machinery in egfr recycling. Biochemistry 2009, 48, 9321–9323.
[CrossRef] [PubMed]
123. Li, X.; Letourneau, D.; Holleran, B.; Leduc, R.; Lavigne, P.; Lavoie, C. Galphas protein binds ubiquitin
to regulate epidermal growth factor receptor endosomal sorting. Proc. Natl. Acad. Sci. USA 2017, 114,
13477–13482. [CrossRef] [PubMed]
124. Deshar, R.; Cho, E.B.; Yoon, S.K.; Yoon, J.B. Cc2d1a and cc2d1b regulate degradation and signaling of egfr
and tlr4. Biochem. Biophys. Res. Commun. 2016, 480, 280–287. [CrossRef] [PubMed]
125. Soubeyran, P.; Kowanetz, K.; Szymkiewicz, I.; Langdon, W.Y.; Dikic, I. Cbl-cin85-endophilin complex
mediates ligand-induced downregulation of egf receptors. Nature 2002, 416, 183–187. [CrossRef] [PubMed]
126. Petrelli, A.; Gilestro, G.F.; Lanzardo, S.; Comoglio, P.M.; Migone, N.; Giordano, S. The endophilin-cin85-cbl
complex mediates ligand-dependent downregulation of c-met. Nature 2002, 416, 187–190. [CrossRef]
[PubMed]
127. Diesenberg, K.; Beerbaum, M.; Fink, U.; Schmieder, P.; Krauss, M. Sept9 negatively regulates
ubiquitin-dependent downregulation of egfr. J. Cell Sci. 2015, 128, 397–407. [CrossRef] [PubMed]
128. Umebayashi, K.; Stenmark, H.; Yoshimori, T. Ubc4/5 and c-cbl continue to ubiquitinate egf receptor
after internalization to facilitate polyubiquitination and degradation. Mol. Biol. Cell 2008, 19, 3454–3462.
[CrossRef] [PubMed]
Cells 2018, 7, 22 21 of 24
129. Malerod, L.; Stuffers, S.; Brech, A.; Stenmark, H. Vps22/eap30 in escrt-ii mediates endosomal sorting of
growth factor and chemokine receptors destined for lysosomal degradation. Traffic 2007, 8, 1617–1629.
[CrossRef] [PubMed]
130. Longva, K.E.; Blystad, F.D.; Stang, E.; Larsen, A.M.; Johannessen, L.E.; Madshus, I.H. Ubiquitination and
proteasomal activity is required for transport of the egf receptor to inner membranes of multivesicular bodies.
J. Cell Biol. 2002, 156, 843–854. [CrossRef] [PubMed]
131. Chi, S.; Cao, H.; Wang, Y.; McNiven, M.A. Recycling of the epidermal growth factor receptor is mediated by a
novel form of the clathrin adaptor protein eps15. J. Biol. Chem. 2011, 286, 35196–35208. [CrossRef] [PubMed]
132. Jopling, H.M.; Odell, A.F.; Pellet-Many, C.; Latham, A.M.; Frankel, P.; Sivaprasadarao, A.; Walker, J.H.;
Zachary, I.C.; Ponnambalam, S. Endosome-to-plasma membrane recycling of vegfr2 receptor tyrosine kinase
regulates endothelial function and blood vessel formation. Cells 2014, 3, 363–385. [CrossRef] [PubMed]
133. Hellberg, C.; Schmees, C.; Karlsson, S.; Ahgren, A.; Heldin, C.H. Activation of protein kinase c alpha is
necessary for sorting the pdgf beta-receptor to rab4a-dependent recycling. Mol. Biol. Cell 2009, 20, 2856–2863.
[CrossRef] [PubMed]
134. Romanelli, R.J.; LeBeau, A.P.; Fulmer, C.G.; Lazzarino, D.A.; Hochberg, A.; Wood, T.L. Insulin-like
growth factor type-i receptor internalization and recycling mediate the sustained phosphorylation of akt.
J. Biol. Chem. 2007, 282, 22513–22524. [CrossRef] [PubMed]
135. Li, X.; Lavigne, P.; Lavoie, C. Gga3 mediates trka endocytic recycling to promote sustained akt
phosphorylation and cell survival. Mol. Biol. Cell 2015, 26, 4412–4426. [CrossRef] [PubMed]
136. Luiskandl, S.; Woller, B.; Schlauf, M.; Schmid, J.A.; Herbst, R. Endosomal trafficking of the receptor tyrosine
kinase musk proceeds via clathrin-dependent pathways, arf6 and actin. FEBS J. 2013, 280, 3281–3297.
[CrossRef] [PubMed]
137. Mihai, C.; Chotani, M.; Elton, T.S.; Agarwal, G. Mapping of ddr1 distribution and oligomerization on the cell
surface by fret microscopy. J. Mol. Biol. 2009, 385, 432–445. [CrossRef] [PubMed]
138. Haugsten, E.M.; Malecki, J.; Bjorklund, S.M.; Olsnes, S.; Wesche, J. Ubiquitination of fibroblast growth
factor receptor 1 is required for its intracellular sorting but not for its endocytosis. Mol. Biol. Cell 2008, 19,
3390–3403. [CrossRef] [PubMed]
139. Decker, S.J. Epidermal growth factor and transforming growth factor-alpha induce differential processing of
the epidermal growth factor receptor. Biochem. Biophys. Res. Commun. 1990, 166, 615–621. [CrossRef]
140. Stern, K.A.; Place, T.L.; Lill, N.L. Egf and amphiregulin differentially regulate cbl recruitment to endosomes
and egf receptor fate. Biochem. J. 2008, 410, 585–594. [CrossRef] [PubMed]
141. Baldys, A.; Gooz, M.; Morinelli, T.A.; Lee, M.H.; Raymond, J.R., Jr.; Luttrell, L.M.; Raymond, J.R., Sr.
Essential role of c-cbl in amphiregulin-induced recycling and signaling of the endogenous epidermal growth
factor receptor. Biochemistry 2009, 48, 1462–1473. [CrossRef] [PubMed]
142. Roepstorff, K.; Grandal, M.V.; Henriksen, L.; Knudsen, S.L.; Lerdrup, M.; Grovdal, L.; Willumsen, B.M.;
van Deurs, B. Differential effects of egfr ligands on endocytic sorting of the receptor. Traffic 2009, 10,
1115–1127. [CrossRef] [PubMed]
143. Sehat, B.; Tofigh, A.; Lin, Y.; Trocme, E.; Liljedahl, U.; Lagergren, J.; Larsson, O. Sumoylation mediates the
nuclear translocation and signaling of the igf-1 receptor. Sci. Signal. 2010, 3, ra10. [CrossRef] [PubMed]
144. Knittle, A.M.; Helkkula, M.; Johnson, M.S.; Sundvall, M.; Elenius, K. Sumoylation regulates nuclear
accumulation and signaling activity of the soluble intracellular domain of the erbb4 receptor tyrosine
kinase. J. Biol. Chem. 2017, 292, 19890–19904. [CrossRef] [PubMed]
145. Deng, H.; Lin, Y.; Badin, M.; Vasilcanu, D.; Stromberg, T.; Jernberg-Wiklund, H.; Sehat, B.; Larsson, O.
Over-accumulation of nuclear igf-1 receptor in tumor cells requires elevated expression of the receptor
and the sumo-conjugating enzyme ubc9. Biochem. Biophys. Res. Commun. 2011, 404, 667–671. [CrossRef]
[PubMed]
146. Visser Smit, G.D.; Place, T.L.; Cole, S.L.; Clausen, K.A.; Vemuganti, S.; Zhang, G.; Koland, J.G.; Lill, N.L. Cbl
controls egfr fate by regulating early endosome fusion. Sci. Signal. 2009, 2, ra86. [CrossRef] [PubMed]
147. Ravid, T.; Heidinger, J.M.; Gee, P.; Khan, E.M.; Goldkorn, T. C-cbl-mediated ubiquitinylation is required
for epidermal growth factor receptor exit from the early endosomes. J. Biol. Chem. 2004, 279, 37153–37162.
[CrossRef] [PubMed]
Cells 2018, 7, 22 22 of 24
148. Severe, N.; Miraoui, H.; Marie, P.J. The casitas b lineage lymphoma (cbl) mutant g306e enhances osteogenic
differentiation in human mesenchymal stromal cells in part by decreased cbl-mediated platelet-derived
growth factor receptor alpha and fibroblast growth factor receptor 2 ubiquitination. J. Biol. Chem. 2011, 286,
24443–24450. [CrossRef] [PubMed]
149. Reddi, A.L.; Ying, G.; Duan, L.; Chen, G.; Dimri, M.; Douillard, P.; Druker, B.J.; Naramura, M.; Band, V.;
Band, H. Binding of cbl to a phospholipase cgamma1-docking site on platelet-derived growth factor receptor
beta provides a dual mechanism of negative regulation. J. Biol. Chem. 2007, 282, 29336–29347. [CrossRef]
[PubMed]
150. Rorsman, C.; Tsioumpekou, M.; Heldin, C.H.; Lennartsson, J. The ubiquitin ligases c-cbl and cbl-b negatively
regulate platelet-derived growth factor (pdgf) bb-induced chemotaxis by affecting pdgf receptor beta
(pdgfrbeta) internalization and signaling. J. Biol. Chem. 2016, 291, 11608–11618. [CrossRef] [PubMed]
151. Takahashi, Y.; Shimokawa, N.; Esmaeili-Mahani, S.; Morita, A.; Masuda, H.; Iwasaki, T.; Tamura, J.;
Haglund, K.; Koibuchi, N. Ligand-induced downregulation of trka is partly regulated through ubiquitination
by cbl. FEBS Lett. 2011, 585, 1741–1747. [CrossRef] [PubMed]
152. Hyndman, B.D.; Crupi, M.J.F.; Peng, S.; Bone, L.N.; Rekab, A.N.; Lian, E.Y.; Wagner, S.M.; Antonescu, C.N.;
Mulligan, L.M. Differential recruitment of e3 ubiquitin ligase complexes regulates ret isoform internalization.
J. Cell Sci. 2017, 130, 3282–3296. [CrossRef] [PubMed]
153. Sharfe, N.; Freywald, A.; Toro, A.; Roifman, C.M. Ephrin-a1 induces c-cbl phosphorylation and epha receptor
down-regulation in t cells. J. Immunol. 2003, 170, 6024–6032. [CrossRef] [PubMed]
154. Fasen, K.; Cerretti, D.P.; Huynh-Do, U. Ligand binding induces cbl-dependent ephb1 receptor degradation
through the lysosomal pathway. Traffic 2008, 9, 251–266. [CrossRef] [PubMed]
155. Duval, M.; Bedard-Goulet, S.; Delisle, C.; Gratton, J.P. Vascular endothelial growth factor-dependent
down-regulation of flk-1/kdr involves cbl-mediated ubiquitination. Consequences on nitric oxide production
from endothelial cells. J. Biol. Chem. 2003, 278, 20091–20097. [CrossRef] [PubMed]
156. Kobayashi, S.; Sawano, A.; Nojima, Y.; Shibuya, M.; Maru, Y. The c-cbl/cd2ap complex regulates vegf-induced
endocytosis and degradation of flt-1 (vegfr-1). FASEB J. 2004, 18, 929–931. [CrossRef] [PubMed]
157. Parks, E.E.; Ceresa, B.P. Cell surface epidermal growth factor receptors increase src and c-cbl activity and
receptor ubiquitylation. J. Biol. Chem. 2014, 289, 25537–25545. [CrossRef] [PubMed]
158. Emdal, K.B.; Pedersen, A.K.; Bekker-Jensen, D.B.; Tsafou, K.P.; Horn, H.; Lindner, S.; Schulte, J.H.; Eggert, A.;
Jensen, L.J.; Francavilla, C.; et al. Temporal proteomics of ngf-trka signaling identifies an inhibitory role for
the e3 ligase cbl-b in neuroblastoma cell differentiation. Sci. Signal. 2015, 8, ra40. [CrossRef] [PubMed]
159. Sirisaengtaksin, N.; Gireud, M.; Yan, Q.; Kubota, Y.; Meza, D.; Waymire, J.C.; Zage, P.E.; Bean, A.J.
Ube4b protein couples ubiquitination and sorting machineries to enable epidermal growth factor receptor
(egfr) degradation. J. Biol. Chem. 2014, 289, 3026–3039. [CrossRef] [PubMed]
160. Gschweitl, M.; Ulbricht, A.; Barnes, C.A.; Enchev, R.I.; Stoffel-Studer, I.; Meyer-Schaller, N.; Huotari, J.;
Yamauchi, Y.; Greber, U.F.; Helenius, A.; et al. A spopl/cullin-3 ubiquitin ligase complex regulates endocytic
trafficking by targeting eps15 at endosomes. eLife 2016, 5, e13841. [CrossRef] [PubMed]
161. Song, R.; Peng, W.; Zhang, Y.; Lv, F.; Wu, H.K.; Guo, J.; Cao, Y.; Pi, Y.; Zhang, X.; Jin, L.; et al. Central role of
e3 ubiquitin ligase mg53 in insulin resistance and metabolic disorders. Nature 2013, 494, 375–379. [CrossRef]
[PubMed]
162. Nagarajan, A.; Petersen, M.C.; Nasiri, A.R.; Butrico, G.; Fung, A.; Ruan, H.B.; Kursawe, R.; Caprio, S.;
Thibodeau, J.; Bourgeois-Daigneault, M.C.; et al. March1 regulates insulin sensitivity by controlling cell
surface insulin receptor levels. Nat. Commun. 2016, 7, 12639. [CrossRef] [PubMed]
163. Sehat, B.; Andersson, S.; Girnita, L.; Larsson, O. Identification of c-cbl as a new ligase for insulin-like growth
factor-i receptor with distinct roles from mdm2 in receptor ubiquitination and endocytosis. Cancer Res. 2008,
68, 5669–5677. [CrossRef] [PubMed]
164. Vecchione, A.; Marchese, A.; Henry, P.; Rotin, D.; Morrione, A. The grb10/nedd4 complex regulates
ligand-induced ubiquitination and stability of the insulin-like growth factor i receptor. Mol. Cell. Biol.
2003, 23, 3363–3372. [CrossRef] [PubMed]
165. Girnita, L.; Girnita, A.; Larsson, O. Mdm2-dependent ubiquitination and degradation of the insulin-like
growth factor 1 receptor. Proc. Natl. Acad. Sci. USA 2003, 100, 8247–8252. [CrossRef] [PubMed]
Cells 2018, 7, 22 23 of 24
166. Monami, G.; Emiliozzi, V.; Morrione, A. Grb10/nedd4-mediated multiubiquitination of the insulin-like
growth factor receptor regulates receptor internalization. J. Cell. Physiol. 2008, 216, 426–437. [CrossRef]
[PubMed]
167. Murdaca, J.; Treins, C.; Monthouel-Kartmann, M.N.; Pontier-Bres, R.; Kumar, S.; Van Obberghen, E.;
Giorgetti-Peraldi, S. Grb10 prevents nedd4-mediated vascular endothelial growth factor receptor-2
degradation. J. Biol. Chem. 2004, 279, 26754–26761. [CrossRef] [PubMed]
168. Hasseine, L.K.; Murdaca, J.; Suavet, F.; Longnus, S.; Giorgetti-Peraldi, S.; Van Obberghen, E. Hrs is a positive
regulator of vegf and insulin signaling. Exp. Cell Res. 2007, 313, 1927–1942. [CrossRef] [PubMed]
169. Ye, Y.; Scheel, H.; Hofmann, K.; Komander, D. Dissection of usp catalytic domains reveals five common
insertion points. Mol. Biosyst. 2009, 5, 1797–1808. [CrossRef] [PubMed]
170. Mevissen, T.E.; Hospenthal, M.K.; Geurink, P.P.; Elliott, P.R.; Akutsu, M.; Arnaudo, N.; Ekkebus, R.;
Kulathu, Y.; Wauer, T.; El Oualid, F.; et al. Otu deubiquitinases reveal mechanisms of linkage specificity and
enable ubiquitin chain restriction analysis. Cell 2013, 154, 169–184. [CrossRef] [PubMed]
171. Seki, T.; Gong, L.; Williams, A.J.; Sakai, N.; Todi, S.V.; Paulson, H.L. Josd1, a membrane-targeted
deubiquitinating enzyme, is activated by ubiquitination and regulates membrane dynamics, cell motility,
and endocytosis. J. Biol. Chem. 2013, 288, 17145–17155. [CrossRef] [PubMed]
172. Abdul Rehman, S.A.; Kristariyanto, Y.A.; Choi, S.Y.; Nkosi, P.J.; Weidlich, S.; Labib, K.; Hofmann, K.;
Kulathu, Y. Mindy-1 is a member of an evolutionarily conserved and structurally distinct new family of
deubiquitinating enzymes. Mol. Cell 2016, 63, 146–155. [CrossRef] [PubMed]
173. Kapoor, N.; Niu, J.; Saad, Y.; Kumar, S.; Sirakova, T.; Becerra, E.; Li, X.; Kolattukudy, P.E. Transcription factors
stat6 and klf4 implement macrophage polarization via the dual catalytic powers of mcpip. J. Immunol. 2015,
194, 6011–6023. [CrossRef] [PubMed]
174. Liang, J.; Saad, Y.; Lei, T.; Wang, J.; Qi, D.; Yang, Q.; Kolattukudy, P.E.; Fu, M. Mcp-induced protein 1
deubiquitinates traf proteins and negatively regulates jnk and nf-kappab signaling. J. Exp. Med. 2010, 207,
2959–2973. [CrossRef] [PubMed]
175. Komander, D.; Clague, M.J.; Urbe, S. Breaking the chains: Structure and function of the deubiquitinases.
Nat. Rev. Mol. Cell Biol. 2009, 10, 550–563. [CrossRef] [PubMed]
176. Grou, C.P.; Pinto, M.P.; Mendes, A.V.; Domingues, P.; Azevedo, J.E. The de novo synthesis of ubiquitin:
Identification of deubiquitinases acting on ubiquitin precursors. Sci. Rep. 2015, 5, 12836. [CrossRef]
[PubMed]
177. Komander, D.; Lord, C.J.; Scheel, H.; Swift, S.; Hofmann, K.; Ashworth, A.; Barford, D. The structure of the
cyld usp domain explains its specificity for lys63-linked polyubiquitin and reveals a b box module. Mol. Cell
2008, 29, 451–464. [CrossRef] [PubMed]
178. Kristariyanto, Y.A.; Abdul Rehman, S.A.; Weidlich, S.; Knebel, A.; Kulathu, Y. A single miu motif of mindy-1
recognizes k48-linked polyubiquitin chains. EMBO Rep. 2017, 18, 392–402. [CrossRef] [PubMed]
179. Sato, Y.; Okatsu, K.; Saeki, Y.; Yamano, K.; Matsuda, N.; Kaiho, A.; Yamagata, A.; Goto-Ito, S.; Ishikawa, M.;
Hashimoto, Y.; et al. Structural basis for specific cleavage of lys6-linked polyubiquitin chains by usp30.
Nat. Struct. Mol. Biol. 2017, 24, 911–919. [CrossRef] [PubMed]
180. Peth, A.; Uchiki, T.; Goldberg, A.L. Atp-dependent steps in the binding of ubiquitin conjugates to the 26s
proteasome that commit to degradation. Mol. Cell 2010, 40, 671–681. [CrossRef] [PubMed]
181. Harrigan, J.A.; Jacq, X.; Martin, N.M.; Jackson, S.P. Deubiquitylating enzymes and drug discovery:
Emerging opportunities. Nat. Rev. Drug Discov. 2018, 17, 57–77. [CrossRef] [PubMed]
182. Duex, J.E.; Sorkin, A. Rna interference screen identifies usp18 as a regulator of epidermal growth factor
receptor synthesis. Mol. Biol. Cell 2009, 20, 1833–1844. [CrossRef] [PubMed]
183. Duex, J.E.; Comeau, L.; Sorkin, A.; Purow, B.; Kefas, B. Usp18 regulates epidermal growth factor (egf)
receptor expression and cancer cell survival via microrna-7. J. Biol. Chem. 2011, 286, 25377–25386. [CrossRef]
[PubMed]
184. McCullough, J.; Clague, M.J.; Urbe, S. Amsh is an endosome-associated ubiquitin isopeptidase. J. Cell Biol.
2004, 166, 487–492. [CrossRef] [PubMed]
185. McCullough, J.; Row, P.E.; Lorenzo, O.; Doherty, M.; Beynon, R.; Clague, M.J.; Urbe, S. Activation of the
endosome-associated ubiquitin isopeptidase amsh by stam, a component of the multivesicular body-sorting
machinery. Curr. Biol. CB 2006, 16, 160–165. [CrossRef] [PubMed]
Cells 2018, 7, 22 24 of 24
186. Savio, M.G.; Wollscheid, N.; Cavallaro, E.; Algisi, V.; Di Fiore, P.P.; Sigismund, S.; Maspero, E.; Polo, S.
Usp9x controls egfr fate by deubiquitinating the endocytic adaptor eps15. Curr. Biol. CB 2016, 26, 173–183.
[CrossRef] [PubMed]
187. Guo, Y.Y.; Lu, Y.; Zheng, Y.; Chen, X.R.; Dong, J.L.; Yuan, R.R.; Huang, S.H.; Yu, H.; Wang, Y.;
Chen, Z.Y.; et al. Ubiquitin c-terminal hydrolase l1 (uch-l1) promotes hippocampus-dependent memory via
its deubiquitinating effect on trkb. J. Neurosci. 2017, 37, 5978–5995. [CrossRef] [PubMed]
188. Mizuno, E.; Kobayashi, K.; Yamamoto, A.; Kitamura, N.; Komada, M. A deubiquitinating enzyme ubpy
regulates the level of protein ubiquitination on endosomes. Traffic 2006, 7, 1017–1031. [CrossRef] [PubMed]
189. Niendorf, S.; Oksche, A.; Kisser, A.; Lohler, J.; Prinz, M.; Schorle, H.; Feller, S.; Lewitzky, M.; Horak, I.;
Knobeloch, K.P. Essential role of ubiquitin-specific protease 8 for receptor tyrosine kinase stability and
endocytic trafficking in vivo. Mol. Cell. Biol. 2007, 27, 5029–5039. [CrossRef] [PubMed]
190. Oh, Y.M.; Lee, S.B.; Choi, J.; Suh, H.Y.; Shim, S.; Song, Y.J.; Kim, B.; Lee, J.M.; Oh, S.J.; Jeong, Y.; et al.
Usp8 modulates ubiquitination of lrig1 for met degradation. Sci. Rep. 2014, 4, 4980. [CrossRef] [PubMed]
191. Berlin, I.; Schwartz, H.; Nash, P.D. Regulation of epidermal growth factor receptor ubiquitination and
trafficking by the usp8.Stam complex. J. Biol. Chem. 2010, 285, 34909–34921. [CrossRef] [PubMed]
192. Reincke, M.; Sbiera, S.; Hayakawa, A.; Theodoropoulou, M.; Osswald, A.; Beuschlein, F.; Meitinger, T.;
Mizuno-Yamasaki, E.; Kawaguchi, K.; Saeki, Y.; et al. Mutations in the deubiquitinase gene usp8 cause
cushing's disease. Nat. Genet. 2015, 47, 31–38. [CrossRef] [PubMed]
193. Smith, G.A.; Fearnley, G.W.; Abdul-Zani, I.; Wheatcroft, S.B.; Tomlinson, D.C.; Harrison, M.A.;
Ponnambalam, S. Vegfr2 trafficking, signaling and proteolysis is regulated by the ubiquitin isopeptidase
usp8. Traffic 2016, 17, 53–65. [CrossRef] [PubMed]
194. Jian, F.; Cao, Y.; Bian, L.; Sun, Q. Usp8: A novel therapeutic target for cushing's disease. Endocrine 2015, 50,
292–296. [CrossRef] [PubMed]
195. Byun, S.; Lee, S.Y.; Lee, J.; Jeong, C.H.; Farrand, L.; Lim, S.; Reddy, K.; Kim, J.Y.; Lee, M.H.; Lee, H.J.; et al.
Usp8 is a novel target for overcoming gefitinib resistance in lung cancer. Clin. Cancer Res. 2013, 19, 3894–3904.
[CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
